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Limited knowledge on the pathogenesis of Mycobacterium tuberculosis (Mtb), 
especially during the latent form of the disease, is the bottleneck of 
discovering novel anti-tubercular drugs/vaccines. The macrophage represents 
the main host cell for Mtb. One of the main strategies for Mtb to survive and 
replicate within the resting macrophage is to arrest phagosomal maturation, a 
process where the Mtb-containing phagosome fuses with lysosomes, which 
contain a range of bactericidal components such as an acidic milieu, 
hydrolyases and cationic peptides. On the contrary, activation of macrophages 
abolishes the inhibition and allows the Mtb-containing phagosome to fuse with 
the lysosomes, thereby translocating mycobacteria into a phagolysosomal 
compartment. While majority of the mycobacteria are killed, the bactericidal 
activity appears to be a protracted event as evidenced by the gradual 
decreasing yet detectable quantity of viable bacilli from Mtb-infected 
activated macrophages over seven days of infection. Gene expression profiling 
studies and gene knock-out approaches have suggested that Mtb responds to 
and has the means to survive within the phagolysosomal environment from 
activated macrophages, and led to the notion that the phagolysosomal 
compartment of activated macrophages may represent a reservoir for latent 
mycobacteria. The work of this thesis thus aims to identify (some of) the 
mechanisms that are involved in Mtb survival within the phagolysosomal 
compartment.  
The first mechanism that we investigated was the role of the mycobacterial 
urease activity in resisting the acidic microenvironment within phagolysosome. 
Previous work conducted with M. bovis BCG has suggested that the 
 ii 
 
mycobacterial urease activity plays a role in Mtb pathogenesis by alkalinizing 
the mycobacterial microenvironment, thereby protecting the bacteria from acid 
stress. Here, we constructed an Mtb urease-deficient strain and confirmed the 
alkalizing effect of the urease activity within the mycobacteria-containing 
vacuole in resting macrophages but not in the more acidic phagolysosomal 
compartment of activated macrophages. Furthermore, the urease-mediated 
alkalizing effect did not confer any growth advantage to Mtb in the activated 
macrophage as evidenced by comparable growth profiles for the mutant, wild 
type (WT) and complemented strains. Instead, the urease-deficient mutant 
exhibited impaired in vitro growth compared to the WT and complemented 
strains when urea is the sole source of nitrogen. Substantial amounts of 
ammonia were produced by the WT and complemented strains, but not with 
the urease-deficient mutant, which represents the actual nitrogen source for 
mycobacterial growth. However, the urease-deficient mutant displayed 
parental colonization profiles in the lungs, spleen and liver in mice. Together, 
our data demonstrated a role for the urease activity in Mtb nitrogen 
metabolism that could be crucial for the pathogen’s survival in nutrient-limited 
microenvironments where urea is the sole nitrogen source. Our work also 
supports the notion that Mtb virulence correlates with its unique metabolic 
versatility which enables this pathogen to utilize any carbon and nitrogen 
sources available in its environment. 
The ability to survive within the phagolysosomal compartment of activated 
macrophages is unlikely to rely on a single bacterial factor. We hence propose 
that a specific set of genes or programme in Mtb may be triggered when the 
mycobacteria-containing vacuole fuses with the lysosome upon macrophage 
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activation. To identify novel genes that are potentially vital for intra-
phagolysosomal survival of Mtb, we developed an in vitro lysosomal exposure 
model, where Mtb is directly exposed to the lysosomal soluble fraction (SF) 
prepared from activated macrophages. RNA-Seq data analysis revealed a 
highly modulated Mtb transcriptome upon exposure to sub-lethal 
concentration of SF. A meta-analysis with Mtb gene expression profiles 
previously generated in several in vivo and in vitro TB infection models 
showed a minimal overlap of the differentially expressed genes between our 
lysosomal exposure model and the other models, highlighting the uniqueness 
of our experimental approach which may allow the identification of novel 
genes involved in Mtb survival within the macrophage. Specifically, we 
observed an enrichment of genes encoding for mycobacterial transporters, 
including rv1258c, which encodes for a Tap-like membrane efflux pump, and 
was further analyzed. We constructed an Mtb rv1258c mutant and observed 
an increased susceptibility to the bactericidal activity of lysosomal SF and 
purified antimicrobial peptides. While the energy-dependent efflux pump 
activity of Rv1258c protein was found responsible for the streptomycin 
resistance observed with an Mtb mutant over-expressing rv1258c, it was not 
involved in its resistance to SF killing. Infectivity and survival of the 
rv1258c mutant were impaired during the first two days post infection of 
resting and activated BMMФs. Reduced bacterial loads during the acute phase 
of TB infection were also observed in mice infected with rv1258c compared 
to the parental strain. Based on the phenotypic observations with the rv1258c 
mutant, we concluded that profiling transcriptional changes of Mtb based on 
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the in vitro lysosomal exposure model is a relevant approach to identify novel 
intra-phagolysosomal survival mechanisms of Mtb. We propose that the efflux 
activity associated with Rv1258c protein is not involved in Mtb survival 
within the phagolysosomal environment. Instead, the membrane-associated 
Rv1258c protein might be involved in the biosynthesis/export of cell wall 
components of Mtb, which represents an important virulence factor for Mtb. 
Work is underway to determine the cell wall composition of the rv1258c 
mutant in comparison with the parental strain.  
 v 
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1.1. Mycobacteria and tuberculosis 
1.1.1. Mycobacteria  
The Mycobacterium genus has more than 120 members (Tortoli, 2003), which 
were identified and classified based on a sequence similarity of 94.3% in the 
16S ribosomal RNA (ROGALL et al., 1990). They are also structurally 
distinguishable by a uniquely complex cell wall envelope, which can be 
differentially stained by the Ziehl-Neelsen acid fast stain for microscopic 
identification. The Mycobacterium genus is generally separated into three 
groups for the purpose of diagnosis and treatment. The Mycobacterium 
tuberculosis complex (MTBC) consists of a group of closely related cultivable 
members that cause tuberculosis in their respective hosts, for instance, M 
tuberculosis (Mtb) in humans, M. bovis in bovids (cattle) and M. pinnipedii in 
marine mammals (Smith et al., 2006). By passaging M. bovis through artificial 
media, Calmette and Guérin generated an attenuated M. bovis, bacille 
Calmette-Guerin (BCG), which is used as a vaccine. The non-cultivable M. 
leprae causes leprosy in humans. The rest of the mycobacteria are classified 
under non tuberculous mycobacteria (NTM) group, which are isolated from 
various environmental sources. They rarely cause pathogenesis, with 
exceptions such as M. kansasii, M. malmoense and M. avium, that are capable 
of causing tuberculosis-like symptoms, especially in immunocompromised 
individuals (Havlik et al., 1993; Horsburgh Jr, 1992; Nightingale et al., 1992; 
Portaels, 1995). M. marinum, M. chelonae and M. fortuitum can cause skin 
and subcutaneous infections (Petrini, 2006).  
Under laboratory conditions, mycobacteria are grown in Lowenstein-Jensen, 
or Middlebrook media supplemented with oleic acid, albumin, dextrose and 
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catalase (OADC). Addition of casein hydrolysate improves the growth of 
some fastidious strains of Mtb (Cohn et al., 1968). Characterized as slow 
growers, the generation time of Mtb is around 24 hours in both synthetic 
medium and in infected animals. On agar, they form sizable colonies with a 
dry and wrinkled surface after 3 to 4 weeks of incubation (Bloom & Murray, 
1992).  
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1.1.2. The burden of tuberculosis 
Mtb is the etiological agent of tuberculosis (TB), an ancient disease that has 
plagued human civilization since its emergence. Highly contagious via air 
transmission, Mtb prevails in living conditions that are crowded and among 
the malnourished, thus becoming a disease of poverty and making the greatest 
impact in developing countries and centres of urban decay in the industrialized 
world, predominately in Asia and Africa (Figure 1.1). Today, the World 
Health Organization (WHO) estimates that a third of the global population is 
infected with Mtb, and reported a total of 8.7 million new TB cases and 1.4 
million TB deaths in 2011. The situation is also compounded by co-infection 
with human immunodeficiency virus (HIV), with 13% of the new cases and 
approximately half a million deaths that are HIV-associated (WHO, 2012). 
Diabetes prevalence also saw a significant increase in the number of people 
with TB (Goldhaber-Fiebert et al., 2011). Complacency and non compliance 
due to the long drug treatment regimen has worsened the global situation, with 
the re-emergence of TB and rapid spread of multi-drug (MDR) and 
extensively-drug resistant (XDR) TB strains (Jain & Mondal, 2008), and the 
recently identified totally-drug resistant (TDR) TB strains (Klopper et al., 
2013; Udwadia & Vendoti, 2013) (Figure 1.2). In 1993, WHO declared TB as 
a global public health emergency, and subsequently launched The STOP TB 
Strategy in 2006. This effort is deemed the most effective strategy in 
combating the spread of TB to date, with the number of new TB cases 
annually and TB mortality rate dropping by 41% since 1990 (WHO, 2012). 
Nevertheless, the global burden of TB still remains high.  
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At the local scene, Singapore reported a slight increase to 1533 new TB cases 
in 2011, with an incidence rate of 40.5 cases per 100,000 of the population 
(MOH, 2012). Older age groups and males present the highest incidence rates 
with 58.2% of the new cases being reported for individuals aged 50 years old 
and above, among which, 69.6% are males. Majority of the TB cases were 
presented as pulmonary TB while extra pulmonary TB constitutes 14.6% of 
the TB cases in Singapore. The incidence of MDR-TB remains low (6 cases 
reported in 2011) despite the high regional prevalence of MDR-TB. Singapore 
continues to emphasize on the strict compliance with treatment under the 
















Figure 1.1: Global incidence of tuberculosis in 2011 (Adapted from Global 
Tuberculosis Report, WHO, 2012). 
 
Figure 1.2: Global numbers of cases of multi-drug resistant tuberculosis 
(Adapted from Global Tuberculosis Report, WHO, 2012). 
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1.1.3. Pathogenesis of tuberculosis 
TB infection begins with the inhalation of a small bacterial load in aerosolized 
droplets into the lung cavity, and presents as two clinical outcomes, active and 
latent tuberculosis. Within the infected population, 90% of the individuals are 
able to control and contain the infection without any signs of symptoms 
(Zumla et al., 2013). The tubercule bacilli persist resiliently within humans for 
lifetime, a phenomenon known as latent TB infection (LTBI), which is further 
discussed in Section 1.2. The remaining 5-10% of the infected population 
develops progressive clinical disease known as primary active tuberculosis in 
their lifetimes (Andrews et al., 2012). The clinical presentation of TB differs 
according to the degree of immunity. Pulmonary TB is the primary 
manifestation of the pathogen, where susceptible patients exhibit classical 
clinical symptoms including chronic cough, sputum production, appetite loss, 
weight loss, fever, night sweats, hemoptysis. Extra-pulmonary tuberculosis 
(EPTB) can also occur and accounts for about 10% of the total new TB cases, 
with a high prevalence in HIV-infected patients (Perronne et al., 1988). With 
no apparent pathology, EPTB has been described at various sites of the human 
host, including the brain, the meninges and the spinal cord, the skin, the 
internal organs, bone and the genitourinary tract (Garcia-Rodriguez et al., 
2011). Inconsistency in TB pathogenesis is also associated with HIV infection, 
from typical pulmonary involvement, to atypical diffuse infection at lower 
lobe, to pulmonary basal involvement, tuberculous pneumonia, hilar or 
mediastinal lymphadenopathies and miliary TB in severely 
immunocompromised HIV-infected patients (Perlman et al., 1997; Smith et al., 
1994). 
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1.1.4. Current diagnostics, treatment and control methods.  
Diagnosis 
The diversity in disease manifestations creates a constant challenge in the 
accurate and rapid diagnosis of TB. Sputum smear microscopy and culturing 
techniques have been standard diagnostic methods of active TB for more than 
a century, with major limitations in detecting childhood TB, drug resistant, 
sputum-negative pulmonary, extrapulmonary and paucibacillary TB (Cuevas, 
2011; Lawn & Zumla, 2011). Furthermore, issues of insensitivity, lack of 
resources to conduct these laboratory-based tests and the prolonged time 
required to get results, have led to inaccurate diagnosis and delays in the 
initiation of, sometimes inappropriate, treatment. TB diagnostics have 
however improved and evolved with technology advancement over the years. 
Advanced imaging techniques such as the use of fluorescence microscopy 
(Steingart et al., 2006), rapid cultures methods and nucleic acid amplification 
tests (NAATs) are few of the latest TB diagnostic developments that have 
been widely implemented in combination with the standard methods for 
enhanced sensitivity (McNerney et al., 2012). The recent endorsement by the 
WHO of Xpert MTB/RIF, a novel NAAT based diagnostic tool that can 
rapidly diagnose TB and rifampicin (RIF) resistant TB within hours (Boehme 
et al., 2010), has accelerated its implementation in 67 countries with high TB 
prevalence (WHO, 2012). Given its excellent specificity of 99-100% in all 
specimens tested, Xpert MTB/RIF also has tremendous potential as non-
sputum based diagnostic tool for extrapulmonary TB (Vadwai et al., 2011). In 
contrast, interferon gamma release assays (IGRAs) and antibody based 
serodiagnostic tests have not substantially improved the diagnostic of active 
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TB due to high cost and poor performance (McNerney et al., 2012). At present, 
a rapid and accurate point-of-care device with the ability to distinguish active 
tuberculosis among various host backgrounds and between latent tuberculosis 
remains of urgent need to be developed (Weyer et al., 2011). 
Treatment and control 
Tuberculosis is a curable disease if the standard TB drug treatment regimen is 
faithfully administered for six months [a combination of rifampicin (RIF), 
isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA) for 2 months, 
followed by a 4-month continuation phase of RIF and INH] upon early and 
accurate diagnosis (WHO, 2012). Non-compliance to the long treatment 
period has led to the emergence of MDR-TB. To halt the spread of MDR-TB, 
the WHO recommends pre-therapy drug susceptibility testing prior to 
initiating a 20-month treatment entailing appropriate second-line drugs, which 
are often associated with multiple (and sometimes serious) side effects and 
lower cure rates. With the same drugs prescribed for HIV-TB co-infections, 
their efficacy and tolerability has been affected by the interactions between 
anti-TB and antiretroviral therapies (Aaron et al., 2004).  Recognising that a 
concerted effort is necessary to reduce the disease burden, the WHO 
developed and strongly encouraged the implementation of the directly 
observed treatment short-course (DOTS) strategy, for countries to better grasp 
the disease situation with thorough disease surveillance, systematic diagnosis 
and treatment, and patient support. It has been proven to be one of the most 
efficient approaches to fight the global TB epidemics (WHO, 2012).  
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1.1.5. Challenges and development in TB drug discovery. 
The standard TB drugs have remained the same for the past 50 years, despite 
having limited efficacy in latent TB and MDR/XDR-TB. The long treatment 
periods and numerous side effects with poor efficacies arising from high 
dosage and drug-drug interactions upon co-administration with other chronic 
disease treatments such as HIV and diabetes have also complicated the control 
of global epidemic.  An ideal TB drug should therefore possess the following 
criteria: (1) shorten treatment duration, (2) target drug resistant strains, (3) 
simplify treatment by reducing pill burden, (4) lower dose frequency, and (5) 
can be co-administered with HIV or diabetes medication (Koul et al., 2011). 
Since the discovery of RIF, the last TB drug found to be efficacious on 
replicating and non-replicating mycobacteria through the inhibition of 
bacterial RNA synthesis (Hartmann et al., 1985), the pipeline has been 
constricted in the last 40 years. The key protracting factor in TB drug 
discovery has been the poor understanding of the proper interactions between 
the pathogen and its host, for Mtb is known to employ diverse strategies to 
survive within its host and evade host immune surveillance. Thus, the lack of 
chemical diversity in drug scaffolds (Payne et al., 2007) combined with in 
vitro target and phenotypic based screening approaches have been 
disappointingly inefficient, yielding only one U.S. FDA approved drug 
candidate, TMC207 or bedaquiline, for the treatment of MDR-TB (Palomino 
& Martin, 2013). The disconnect between in vitro efficacy of the drug 
candidate and  its in vivo killing ability represents a major caveat in all the in 
vitro-based drug screening approaches as some targets identified in vitro are 
actually dispensable or irrelevant in vivo (Pethe et al., 2010). The single 
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culture condition screening strategy is also inadequate in capturing all the 
mycobacterial persisters, which are survivors of antibiotic exposure, given 
their heterogeneous nature. There is also a lack of biomarkers or surrogate 
endpoints, and relevant in vivo TB models that can reliably predict the success 
or failure of the drug candidates in the early course of treatment. 
Nevertheless, the pipeline has been slowly expanding with 10 TB drug 
candidates in pre-clinical and clinical development (Figure 1.3) (Villemagne et 
al., 2012). Re-engineering existing drug classes, understanding the 
physiochemical features of TB drugs, targeting host-pathogen signaling 
pathways and improving screening platforms are some new strategies to help 
accelerate TB drug discovery (Koul et al., 2011). Very recently, a high content 
screening technology in infected macrophages has identified a promising class 
of imidazopyridine amide (IPA) compounds that block Mtb growth by 
targeting the respiratory cytochrome bc1 complex. The optimized IPA 
compound Q203 is equally active against MDR clinical isolates at low doses, 
indicating its potential as new clinical candidate (Pethe et al., 2013).  Several 
pharmaceutical companies and non-governmental organizations have also 
launched a recent initiative (Critical Path to New TB Regimens (CPTR)) to 
develop new drug regimens which comprised of investigational TB drugs and 
existing or TB drug candidates, to avoid developing each drug and thus 
shorten the development timeline (Spigelman et al., 2010). 













Figure 1.3: Antitubercular compounds in development and their targets. 
(Reprinted from European Journal of Medicinal Chemistry, Vol 51, 
Villemagne et al, Tuberculosis: The drug development pipeline at a glance, 1-
16, Copyright (2012), with permission from Elsevier.) 
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1.1.6. TB vaccine development 
Being the only TB vaccine available, the live BCG vaccine is able to protect 
newborns against the severe forms of TB but not pulmonary TB in adults. 
Prior exposure to environmental mycobacteria (Brandt et al., 2002; Palmer & 
Long, 1966) or variation in genetic/antigenic composition of locally 
established BCG vaccine strains (Behr, 2001; Oettinger et al., 1999) might 
have led to its waning efficacy in adults. WHO thus recommends mandatory 
immunization for children at birth in TB-endemic areas, BCG-vaccinated 
individuals who remain tuberculin skin test (TST) negative, and high risk 
groups in low burden countries (WHO, 2012). As vaccination is the most 
effective strategy to curb the spread of TB epidemic, it is of utmost priority for 
TB researchers to develop a novel and efficacious vaccination strategy. 
Leading TB vaccines candidates are designed based on two aims, to improve 
the immunogenicity of the BCG vaccine, or enhance the immune response 
primed by BCG. The immunogenicity of BCG can be promoted by re-
introducing highly immunogenic Mtb antigens into BCG. Live recombinant 
BCG (rBCG) strains over-expressing immunogenic Mtb antigens, such as 
Ag85B and proteins encoded by the RD-1 region (ESAT-6 and CFP-10) have 
significantly improved the effects of BCG vaccination, as shown by studies in 
animal models (Horwitz & Harth, 2003; Pym et al., 2003). Kaufmann and 
colleagues also developed rBCG strains expressing membrane-perforating 
cytolysins (listerolysin and perfringolysin) to better optimize the export of 
BCG antigens in infected macrophages, leading to improved stimulation of 
CD8+ and CD4+ T cells, which is a current limitation of the BCG vaccine 
(Conradt et al., 1999; Desel et al., 2011; Grode et al., 2002; Grode et al., 
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2005b; Sun et al., 2009b). Substituting BCG with live attenuated Mtb strains is 
another approach of live TB vaccine, as exemplified by the rMtb 
phoPfad26 vaccine candidate (Asensio et al., 2008). An alternative 
vaccination strategy is to administer booster vaccines to sustain the immune 
response elicited by the BCG vaccine. Typically, booster vaccines are viral 
vectored or adjuvanted purified protein based, and express one or fused 
secreted mycobacterial antigens of strong immunogenic properties to elicit Th-
1 type immune response which is expected to contain the infection and reduce 
the risk of developing active TB. Derrick and colleagues also discovered novel 
Mtb antigens (Rv1626, Rv1735, Rv1789, Rv2032, Rv2220, and Rv3478) of 
strong immunogenicity, as evidenced by their ability to significantly reduce 
bacterial burdens in the lungs of mice when vaccinated with the recombinant 
proteins (Derrick et al., 2013). All these strategic vaccine designs have 
produced a substantial portfolio of TB vaccine candidates in clinical 
development (Figure 1.4) (Kaufmann, 2012), with viral vectored based 
vaccines, Crucell Ad35/AERAS-402 and MVA85A/AERAS-485, having 
successfully entered Phase IIb of clinical trials.  A recent Phase IIb infant 
trial had showed that MVA85A/AERAS-485  was safe, but not significantly 
effective in protecting BCG-vaccinated infants from TB disease, although the 
candidate’s safety and immunogenicity in an HIV+ adult population as well as 
a trial in HIV-exposed infants are still ongoing (AERAS, 2013). 
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Figure 1.4: Status of TB vaccine candidates in clinical trials in 2011. 
(Reprinted from Trends in Immunology, Vol 33/7, Kaufmann, Stefan H. E., 
Tuberculosis vaccine development: strength lies in tenacity, 373-379., 
Copyright (2012), with permission from Elsevier.) 
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1.1.7. Drug resistant (MDR, XDR and TDR) versus drug tolerant TB. 
The mismanagement of TB cases has led to the emergence of drug resistant 
Mtb strains, with Eastern Europe and the Central Asia constituting the highest 
proportions of TB patients with MDR-TB (WHO, 2012). Drug resistance in 
TB is defined as an infection with an Mtb strain that is resistant to INH and 
RIF (MDR-TB), or at least one of the first line drugs, in addition to any 
fluoroquinolones and at least one of three injectable second-line drugs (XDR-
TB). Despite the improvement in diagnosis of MDR–TB strains with Xpert 
MTB/RIF, detection of XDR-TB strains solely relies on the slow culture 
techniques, thus delaying treatment of a 20-month regime of a combination of 
first and second –line drugs. Mtb acquires drug resistance through genotypic 
or phenotypic alterations. At a non-sterilizing drug concentration, spontaneous 
chromosomal mutations were found to occur on genes involved in the 
activation or the target of the drug, such as katG and aphC in INH activation, 
inhA, rpoB and gyrB as targets of INH, RIF and fluoroquinolones respectively 
(Campbell et al., 2011; Hazbón et al., 2006), thereby conferring inheritable 
drug resistance in clinical isolates of Mtb. On the contrary, occurrence of 
phenotypic drug resistance in Mtb is often the consequence of non-drug 
related physiological changes in Mtb induced by its microenvironments. For 
instance, Mtb showed INH tolerance due to an over-expression of 
mycobacterial DNA-binding protein 1 (MDP1), a histone-like protein 
conserved in mycobacteria, which negatively regulates katG transcription 
through binding to its promoter region during stationary growth (Niki et al., 
2012). Similarly, the macrophage-induced over-expression of rv1258c, which 
encodes for a Tap efflux pump, has conferred intrinsic tolerance to RIF in 
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replicating mycobacteria (Adams et al., 2011). The formation of biofilms has 
also been proposed to impart drug tolerance in Mtb, which exhibits antibiotic 
recalcitrance and chronic infection, which are characteristics of infections 
associated with microbial biofilms (Islam et al., 2012). Mycobacterial 
persisters, defined as survivors from antibiotic exposure, are drug tolerant at 
point of exposure, but are drug susceptible and replicate actively when 
antibiotics are removed. However, intermittent drug dosing, a treatment 
regimen proposed to eliminate the persisters (Bigger, 1944), increases the risk 
of developing drug resistant strains, especially when the bacterial load is high 
(Zhang et al., 2012). Due to the nature of its occurrence, phenotypic drug 
tolerance is non-inheritable and hence remains tricky to detect.  
Chapter 1: Literature review 
17 
 
1.1.8. Host innate immunity and defense mechanisms. 
With a very low percentage (5-10%) of the infected population developing 
active tuberculosis, the host innate immunity does play an important role in 
curbing the initial manifestation of the pathogen. One of the early immune 
responses is exerted through the macrophages. Recognition and uptake of Mtb 
activate the microbicidal capacity of the macrophage, which leads to the 
production of reactive oxygen intermediates (ROI) and reactive nitrogen 
intermediates (RNI) respectively to aid intracellular killing of the engulfed 
bacilli (Bedard & Krause, 2007; Nathan & Shiloh, 2000; Yang et al., 2012). 
As illustrated in Figure 1.5, activation of the macrophage also induces the 
formation of phagolysosomes through the fusion of the phagosome-
encapsulated Mtb with the acidic and hydrolytic lysosomal compartments, 
thereby leading to the killing of mycobacteria (Philips & Ernst, 2012). 
Interferon gamma (IFN-or Vitamin D3 (VD) - induced autophagy was also 
proposed to contribute to mycobacterial clearance through the production and 
delivery of peptide-conjugates possessing antimicrobial properties upon the 
fusion with autolysosomes (Alonso et al., 2007; Yuk et al., 2009). Mtb also 
activates the production of anti-microbial peptides such as human defensins 
(Rivas-Santiago et al., 2006) and cathelicidin LL-37 (Rivas-Santiago et al., 
2008) by infiltrating neutrophils, and exert their bactericidal effect on 
intraphagosomal bacilli when transferred to phagolysosomes (Tan et al., 2006) 
or on extracellular bacilli when released into the extracellular space (van 
Wetering et al., 2005), although many reports also support a negative role of 
neutrophils in TB pathogenesis in genetically susceptible mouse strains 
(Eruslanov et al., 2005; Keller et al., 2006) and active TB patients, where 
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respiratory failure and mortality are associated with increased blood 
neutrophils levels (Barnes et al., 1988). A repertoire of cytokines, notably 
tumour necrosis factor alpha (TNF- and IFN-, produced by a variety of 
immune cell populations clearly demonstrated a protective role in tuberculosis 
through immune cell recruitment to the infection site and activation for the 
killing of intracellular mycobacteria,  initiating adaptive immunity, and the 
cross-regulation of cytokine production (van Crevel et al., 2002).  
 
Figure 1.5: Possible fates of intracellular Mtb. (a) Mtb can prevent 
phagosome maturation and grow in an early endosome-like compartment, (b,c) 
permeabilizes the phagosomal membrane, either allowing direct cytosolic 
access or escape into the cytocol, (d) be re-sequestered back into a membrane-
bound compartment. Some ingested bacteria failed to prevent phagosome 
maturation and are translocated into the phagolysosomal compartment, where 
its replication is (e) curtailed or (f) permitted. (g) IFN-and vitamin D3 can 
overcome the phagosome maturation arrest by Mtb and promote its delivery 
into autolysosomes, which is bactericidal. (Reprinted from Annual Review of 
Pathology: Mechanisms of Disease, Vol 7/1, Philips & Ernst, Tuberculosis 
Pathogenesis and Immunity, 353-384., Copyright (2012), with permission 
from Annual Reviews.) 
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1.1.9. Subversion of host immunity 
Despite the vigorous launch of host immunity, Mtb is able to evade host 
immune surveillance to establish a latent infection within the host, as 
evidenced by the delayed time necessary to trigger adaptive immune response 
in Mtb-infected humans and mice, compared to other bacterial pathogens. 
Indeed, Mtb was found to interfere with processes within the macrophages, 
that resulted in a reduced expression of major histocompatibility complex 
(MHC) class  II molecules (Noss et al., 2001; Pai et al., 2003; Wojciechowski 
et al., 1999) and ability in antigen loading (Hmama et al., 1998), consequently 
leading to the suboptimal activation of CD4+ effector cells for proliferation 
and cytokine production (Bold et al., 2011; Egen et al., 2011; Pancholi et al., 
1993). Mtb was also reported to inhibit multiple IFN-γ-dependent host defense 
mechanisms (Pai et al., 2003; Ting et al., 1999). Studies have also indicated 
that Mtb induces the immunosuppressive activity of macrophages (Tomioka et 
al., 2012) to produce cytokines such as interleukin-10 (IL-10) and 
transforming growth factor beta (TGF-, which impaired the ability of 
macrophages to stimulate immune effector cells effectively and enhanced the 
intracellular growth of Mtb (Hirsch et al., 1994; Hirsch et al., 1996; Oswald et 
al., 1992).  
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1.2. Latent tuberculosis 
1.2.1. Clinical aspects 
The true success of Mtb as a human pathogen lies in its unique ability to cause 
latent infection, a clinical observation of TB infection without apparent disease. 
Latently infected individuals are therefore not infectious and do not show 
signs of healed TB disease in their chest radiographs, despite a positive result 
in TST reaction to purified protein derivative (PPD) or IGRAs to Mtb-specific 
antigens. While there is a 10% risk of reactivation throughout the lifetimes of 
infected individuals (Sutherland, 1976; Vynnycky & Fine, 1997), defects in 
cell-mediated immunity resulting from HIV infection, malnutrition, or 
chemotherapy, steroid and anti-tumor necrosis factor treatments predispose 
reactivation with an increased risk by 5-10%. The preferred regimen is INH 
alone for nine months or for a longer duration in HIV-infected persons in areas 
with a high prevalence of tuberculosis (Martinson et al., 2011). 
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1.2.2. Life within a granuloma 
The granuloma is a pathological hallmark of TB. It is an organized structure of 
immune cells developed by the host in response to the antigenic stimuli of the 
bacilli, and thought to control the infection and eradicate the infecting bacilli. 
The formation of a classic TB granuloma begins with the uptake of the bacilli 
by the alveolar macrophages, which leads to the production of cytokines and 
chemokines and their receptors on the immune effector cells, thereby 
promoting the infiltration of other immune cells (macrophages, neutrophils, 
dendritic cells, and lymphocytes) to the infection site (Saunders & Britton, 
2007) with an orchestrated production of cytokines, such as TNF-, IL-12 and 
IFN-, which have been shown to be critical in the control of TB infection 
(Alcaïs et al., 2005; Alcaïs et al., 2010; Keane et al., 2001). Stimulated 
macrophages are also differentiated into multinucleated langhans giant cells 
(MGCs), foamy macrophages loaded with lipid droplets, and epithelioid cells 
(Russell et al., 2009).  Subsequently, these cells are organised into a spherical 
structure with infected macrophages in the center and surrounded by various 
categories of lymphocytes (B cells, CD4+, CD8+, and γ/δ T cells) (Peters & 
Ernst, 2003) and fibroblasts, the latter creating a peripheral fibrotic capsule. 
The extensive inflammatory response within the granuloma may also cause 
tissue necrosis, leading to the formation of a caseous core, a classical feature 
of human TB granulomas. While the adverse conditions within the granuloma 
appear bactericidal, live bacilli have been isolated from lungs of individuals 
with clinically inactive tuberculosis (Aronson & Whitney, 1930), indicating 
that this organism can persist in a granulomatous lesion for many years, and 
thus likely responsible for TB latency. Therefore, it is a long standing 
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paradigm that such a niche environment of the granuloma induces the bacilli to 
enter a state of bacteriostasis or very slow replication with low metabolic 
activity sufficient for long periods of sustainability, and retain the ability to 
resume growth under permissive conditions leading to active disease. However, 
recent human and non-human primate studies indicated that immune responses 
across infected individuals, granuloma types within individuals, infection 
outcomes and treatment responses occur in a spectrum, which strongly 
supports the existence of heterogeneity within the classification of active and 
latent TB (Barry et al., 2009; Gideon & Flynn, 2011; Young et al., 2009). 
Moreover, recent evidence indicates that, in some models of persistence, a 
subpopulation of bacteria are actively replicating (Gill et al., 2009). It thus 
appears that much needs to be done to understand fully latent TB. 
At the cellular level, the macrophage is widely acknowledged as the primary 
host cell of Mtb, as they are one of the first cell types that Mtb encounters 
upon entry into the lung cavity, and forms the largest population of immune 
cells within the granuloma. More importantly, the interaction between the host 
macrophage and the tubercule bacilli is believed to be one of the key factors 
contributing to TB latency. Hence, the persistence of Mtb has been 
characterized as (i) the capacity of the pathogen to reside within macrophages, 
(ii) avoiding elimination by the host immune response, and (iii) slowing the 
rate of clearance by anti-TB drugs (Gomez & McKinney, 2004). 
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1.2.3. Factors that drive TB latency 
From a variety of human, animal and in vitro studies, hypoxia and nutrient 
starvation are proposed to represent the key host-induced stresses that drive 
TB latency. 
Several indirect evidences have postulated a prominent role for oxygen status 
in TB latency and reactivation. It has been observed that within the lungs of 
patients failing TB chemotherapy, lesions lacking direct contact with air are 
paucibacillary (Kaplan et al., 2003). More evidently, pulmonary TB and 
reactivation from latency in humans are preferentially associated with oxygen-
rich parts of the body, such as the upper lobes of the lungs (Adler & Rose, 
1996). At the molecular level, transcriptional activities of icl, narX, and 
rv2557 and rv2558, which have been implicated in the persistence of the 
bacterium within the host, were found to be increased in both dormant 
mycobacteria from the hypoxic Wayne model and the tuberculous granulomas 
in lung tissue sections from tuberculosis patients (Fenhalls et al., 2002). 
Recently, an in vivo study has convincingly proven this hypothesis to be true. 
Using an oxygen probe to measure the level of oxygen within the granuloma, 
Via and colleagues have demonstrated that pulmonary lesions present in 
guinea pigs, rabbits, and nonhuman primates, even as small as 3mm, were 
severely hypoxic. A reduced bacterial load in the lungs of infected rabbits was 
also observed with the administration of metronidazole, known to have potent 
bactericidal activity in vitro only under low-oxygen culture conditions (Via et 
al., 2008). Taken together, these observations therefore support that hypoxia 
defines the microenvironment within the granuloma to a certain extent.      
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Nutrient starvation is also implicated in TB latency based on the rationale that 
insufficient nutrients lead to non-growth in bacteria. Indeed, there is some 
evidence suggesting that persisting mycobacteria in lung lesions are 
nutritionally starved. Mtb isolated from lung lesions was found to display 
altered morphology and staining properties, which are similar to mycobacteria 
grown in distilled water. Moreover, they can also survive for at least two years 
without the presence of nutrients and then recover rapidly when fresh nutrients 
are encountered (Nyka, 1967; Nyka, 1974). Restricted mycobacterial growth 
was also observed within an inorganic phosphate limiting environment, with a 
phenotypic resistance to INH, a first line anti-TB drug that is only active on 
replicating bacilli (Rodriguez et al., 2002b). The response of Mtb to scavenge 
for nutrients essential for growth, especially within its primary host cell, the 
macrophage could also indicate nutrient limitation within their 
microenvironment. The formation of foamy macrophages induced by Mtb 
oxygenated mycolic acids  (Peyron et al., 2008) has been speculated as a 
nutrient source for the bacterium within the granuloma (Russell et al., 2009), 
given its preference for fatty acids during intracellular persistence. Similarly, 
siderophores are produced by Mtb to scavenge for iron, an essential metal ion 
for bacterial growth. At the transcriptional level, nutrient starvation induces a 
larger number of stress-responsive genes (Betts et al., 2002) compared to other 
stresses, (Fisher et al, 2002) (Park et al, 2003), either as a single-stress  (Fisher 
et al., 2002a; Park et al., 2003) or as part of a multiple-stress (Deb et al., 
2009b) in vitro model. Notably, this set of genes was also found up-regulated 
in dormant bacilli cultured in the hypoxic Wayne model (Deb et al, 2009). 
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While hypoxia and nutrient starvation are factors that are suggested based on 
the assumption that the granuloma is the sanctuary of persisting Mtb, it is also 
important to note that Mtb could also be taken up by other cell types such as 
adipocytes (discussed in Section 1.3.3), upon dissemination. The contribution 
of such niche microenvironments to TB latency remains to be studied.  
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1.2.4. Models of TB latency 
One major hurdle of investigating TB latency lies particularly in the 
availability and relevance of experimental models. At present, there are a 
number of in vitro models that have incorporated factors and conditions 
postulated to induce TB latency, and a limited choice in ex/in vivo models that 
could accurately reflect LTBI in humans.   
1.2.4.1. In vitro models 
Wayne’s hypoxia-induced model 
The Wayne hypoxia-induced model mimics the state of Mtb surviving in 
closed, necrotic lesions during clinical latency. It involves a slow and 
progressive oxygen depletion within a sealed, stirred culture tube of specific 
dimensions, which mimics the oxygen exposure bacilli encounter within the 
granuloma (Wayne & Hayes, 1996). Aerobic cultures with replicating bacilli 
are subjected to very gentle stirring. Upon the gradual assimilation of oxygen 
to approximately 1% saturation in the culture, the bacilli enters the 
microaerophilic non-replicating phase (NRP) 1, defined by a slow rate of 
increase in turbidity without a corresponding increase in the bacterial CFU or 
DNA synthesis. Cells remain viable with a steady ATP production and at high 
rate of production of glycine dehydrogenase, an enzyme previously speculated 
for regenerating NAD as an adaptation to hypoxic conditions (Wayne & Lin, 
1982; Wayne, 1994). As the oxygen saturation drops below 0.06%, the bacilli 
shifts down rapidly into an anaerobic NRP2 phase, ATP production decreased 
slight but was maintained with no further increase in turbidity, although 
glycine dehydrogenase markedly declined. The slow depletion of oxygen is 
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deemed responsible for activating the dormancy program in Mtb, which 
involves shutting down cell division and DNA synthesis (Wayne & Hayes, 
1996), restricting biosynthetic activity, exploiting alternative energy sources 
and developing mechanisms to stabilize cell components (Wayne & Lin, 
1982). Moreover, with a drug susceptibility profile resembling that of latent 
TB infections, these dormant bacilli therefore resemble bacilli that cause latent 
TB, with the capacity to revive and reactivate disease under favorable 
conditions (oxygenated conditions) at a later time. The Wayne model is 
probably a good simulation of the hypoxic condition encountered within the 
granuloma as transcriptomes of hypoxia-induced bacilli and ex/in vivo models 
of TB have indicated some significant overlap in particular activation of the 
dosR regulon and icl gene (Muttucumaru et al., 2004; Schnappinger et al., 
2003; Talaat et al., 2004; Voskuil, 2004). Nonetheless, extrapolation of data 
generated in the Wayne model remains speculative, since the location and 
physiological state of the tubercle bacilli during latency have not been firmly 
established. 
Loebel’s nutrient starvation model 
In the Loebel’s nutrient starvation model, normal-growing mycobacteria are 
transferred from a nutrient-rich medium to phosphate buffer saline only and 
incubated for six weeks at 37ºC in order to starve the cells (Loebel et al., 
1933a; Loebel et al., 1933b). Measured by a manometer, these starved cells 
exhibited a gradual shutdown of respiration to minimal levels but were able to 
recover when returned to rich medium. Like dormant cells from the Wayne 
model, the starved cells also exhibited phenotypic tolerance to INH, RIF and 
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metronidazole. This model therefore represents the notion that low respiration 
in bacilli can also be achieved through nutrient starvation despite aerobic 
conditions, which is in contrast with the Wayne model.  
Single and Multiple-stress model 
As Mtb receives multiple signals in vivo, it is likely that in vivo persistence is 
being established in response of Mtb to several environmental stresses that 
exist within the granuloma. Deb and colleagues developed a multiple-stress 
dormancy model that combined stresses of low oxygen (5%), high CO2 (10%), 
low nutrient (10% Dubos medium) and acidic pH (5.0), conditions that Mtb is 
thought to encounter in the host (Deb et al., 2009a), to mimic the 
microenvironment within the granuloma. When grown in these conditions, 
Mtb cells do not show acid-fast staining, but contain lipid inclusion bodies and 
develop resistance to drug such as INH and RIF, fulfilling the criteria of 
dormant bacilli. While it seems an appropriate model for latency, it has not 
been widely used for drug screening. Recently, our laboratory also described 
an anaerobic shift-down assay to model the translocation of the bacilli into a 
phagolysosome, a niche microenvironment in which the bacilli is believed to 
persist within the macrophage (Tan et al., 2010). Aerated Mtb cultures are 
transferred into culture media adjusted to an acidic pH of 5.5 depleted of 
oxygen within 24 hours and incubated for 10 days. Non-replicating yet viable 
bacilli were detected although the drug susceptibilities for these non-
replicating bacteria have not been tested.   
On the contrary, single stress models enable researchers to dissect the 
regulation of sets of genes which are specific to the stress applied.  
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Mycobacterial responses to heat shock (Stewart et al., 2002), acid (Fisher et 
al., 2002b), nitric oxide (Ohno et al., 2003; Voskuil et al., 2003), hydrogen 
peroxide (Voskuil et al., 2003) and iron starvation (Rodriguez et al., 2002a) 
have been studied.  
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1.2.4.2. Ex vivo and in vivo models 
Macrophage infection model 
It is no doubt that the macrophage infection model has contributed 
significantly to the understanding of host-pathogen interactions during Mtb 
infection and discovery of numerous mycobacterial factors that are involved in 
Mtb persistence and its subversion of the host immunity. Primary 
macrophages such as murine bone marrow derived macrophages (BMMФ) 
(Abramovitch et al., 2011; Pethe et al., 2004), human mononuclear derived 
macrophages (MDM) (Welin et al., 2011) and alveolar macrophages isolated 
from mice and macaques (Pacheco et al., 2013) are well-accepted and used for 
their biological relevance, as demonstrated by their ability to control Mtb 
replication during infection for up to nine days. However, due to the laborious 
process of obtaining primary macrophages and batch variation in 
isolated/differentiated cells, secondary cell lines such as RAW 264.7 (murine) 
(Dunphy et al., 2010; Pan et al., 2012) and THP-1 (human) macrophages (Wu 
et al., 2012) are also commonly employed, typically for short period studies 
conducted within two days. Nonetheless, cell viability of both macrophage 
cultures declines over a short time period, which prevents the study of long 
persistence of Mtb. Estrella and colleagues recently showed that activation 
with Vitamin D3 (VD) and retinoic acid (RA) increases the viability of THP-1 
macrophages considerably for up to 35 days after Mtb infection with a 
constant bacterial load, compared to the classical phorbol myristate acetate 
(PMA) activation (Estrella et al., 2011). Furthermore, these infected RAVD-
activated macrophages were able to form MNGCs after 30 days which were 
found to contain non-replicating persisting Mtb after more than 60 days in 
Chapter 1: Literature review 
31 
 
culture. The ability to produce persistent Mtb in the RAVD induced 
macrophage model is therefore an added advantage over existing macrophage 
models to study persistence of intracellular Mtb at the cellular level, and 
develop therapeutic approaches and investigate the pathogenesis of latency.  
Rodents  
The murine model is the most commonly used in vivo model of TB, due to the 
ease of manipulation and housing, readily availability of genetically altered 
strains and the wide range of available research-grade reagents. A progressive 
infection of TB can be established in mice through the inoculation of the 
bacilli via various routes, including the natural mode of transmission, 
aerosolization, which is performed in a chamber. One major caveat of the 
murine model is the impossibility to establish latent TB naturally as bacterial 
numbers remain very high, which is in contrast to the reduced bacterial load 
observed in humans, despite the onset of adaptive immunity three weeks after 
infection (Munoz-Elias et al., 2005; Rhoades et al., 1997). The Cornell murine 
model was developed to mimic latent tuberculosis by administering antibiotics 
to reduce the high bacterial loads to very low or non-detectable levels 
(McCune et al., 1956), but its relevance to human latent TB remains 
ambiguous. Furthermore, TB infected mice appear to trigger more robust 
immune responses, and do not reproduce the pathology, complexity and 
heterogeneity of human lesions, such as caseous necrosis and cavity formation 
(Tsai et al., 2006). Tubercule bacilli are thus not exposed to the same 
microenvironments of the granulomas as found in humans, which limits 
extrapolation of the data generated in the mouse model. Nevertheless, the 
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murine model remains a popular choice to model TB for the study of Mtb 
mutants and effectiveness of potential drug and vaccine candidates prior to 
clinical trials. Mice with genetic deletions in genes encoding for IL-12 
(Cooper et al., 1997), IFN-(Flynn et al., 1993) and TNF-Flynn et al., 
1995), or depletion of CD4+ T cells (Mogues et al., 2001), have validated the 
importance of these immune factors in granuloma formation and control of 
Mtb infection. In contrast, higher order rodents such as rabbits and guinea pigs 
are able to form granulomas upon TB infection that are remarkably similar to 
humans (Lenaerts et al., 2007; Manabe et al., 2008). However, guinea pigs are 
believed to be very susceptible to TB infection, while rabbits are only 
susceptible to certain highly virulent Mtb strains. Also, there is a limited 
availability of molecular and immunological research tools for both models, 
rendering them a secondary choice of in vivo model of TB. Nevertheless, the 
guinea pig model has been commonly used for vaccine testing, with the 
rationale that the best vaccine candidate needs to be protective against the 
most susceptible host.  
Non-human primates 
Non-human primates (NHPs), such as rhesus and cynomolgus macaques, can 
be considered the most biologically relevant animal model of TB to date. Due 
to several similarities shared with humans, at the genomic, immunological and 
physiological levels, researchers can induce asymptomatic, chronic latent or 
acute rapidly fatal pulmonary TB by varying the dosage of the bacterial 
inoculums used to infect the NHPs (Safi et al., 2003; Walsh et al., 1996).  
Most importantly, like humans, they are able to develop a complete spectrum 
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of granulomatous lesions that also found in human disease (Capuano et al., 
2003). It is also a potential model for TB/HIV co-infection and reactivation, 
given that post primary lesions were formed in vicinity of primary lesions 
upon co-infection with simian immunodeficiency virus (SIV) in rhesus 
macaques (Mehra et al., 2011). Given the extensive similarity, detection 
techniques and tools developed for humans can be applicable to NHPs, and 
vice versa. For instance, the assessment of antigen-specific immunological 
responses is via the tuberculin skin test or PRIMAGRAM, an IFN- release 
assay developed specifically for primates. The use of X-ray computed 
tomography (CT) or coupled with positron emission tomography (PET) is also 
applicable to NHPs for researchers to study the functional and structural 
aspects of the development and progression of pulmonary granulomatous 
lesions without any invasive procedure involved. There is also an increasing 
use of the NHP models to study the mechanisms of pathogenesis through the 
Mtb mutant libraries, and host gene expression in tuberculous lesions using 
rhesus macaque-specific whole-genome microarrays, and have yielded 
meaningful insights to the robustness of immune responses of NHP during TB 
infection (Dutta et al., 2010; Mehra et al., 2010).  
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1.2.5. Identifying mycobacterial virulence factors 
The genome sequencing of Mtb H37Rv had provided the initial basis to 
speculate conserved pathways that might be involved in virulence of Mtb, 
which was subsequently confirmed by single gene deletion studies to 
determine the essentiality of these pathway-related genes in Mtb survival and 
persistence in ex vivo and in vivo models. To cast a wider net, Mtb libraries 
were generated based on transposon mutagenesis and screened in in vitro 
growth conditions (Sassetti et al., 2003), macrophages (Pethe et al., 2004) and 
lungs of mice (Camacho et al., 1999), leading to the  identification of many 
mycobacterial genes that are essential for Mtb growth in each of these models. 
Besides the loss or gain of gene function, bacterial pathogens adapt to their 
host environments by switching on complex transcriptional programmes. 
Profiling the proteome and transcriptome of in vivo Mtb thus became a 
‘turning point’ approach in understanding its virulence.  As of today, more 
than 50 microarrays have been reported, and highlighted pathways that are 
likely to be important during Mtb pathogenesis (Kendall et al., 2004). 
Moreover, gene expression profiling has also allowed comparison among the 
various existing TB models. For instance, a comparison of the microarray data 
revealed that less than 10% of genes up-regulated by Mtb in human 
macrophages (Cappelli et al., 2006) were shown to be induced in mouse 
macrophages (Schnappinger et al., 2003) and mouse infection of Mtb (Timm 
et al., 2003). The recent development of a third generation sequencing 
technique, known as RNA sequencing, has a greater detection sensitivity 
compared to that of the microarray technique by directly sequencing and thus 
quantifies every RNA (cDNA) molecule (Croucher et al., 2009). This 
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technique has unexpectedly revealed that Mtb also transcribes a wide range of 
non-coding small RNA transcripts (sRNAs) in addition to the coding 
transcriptome, representing a possibility of an innate gene regulatory 
mechanism in Mtb (Arnvig et al., 2011) that might influence the physiological 
behavior of Mtb during infection. This could ultimately impact the bacterium 
at the translational level, highlighting the importance of proteomics studies in 
Mtb (Kruh et al., 2010; Starck et al., 2004). Reconstruction of biological 
networks pertaining to the pathogenesis of Mtb using computational methods 
allows simulation studies to be conducted, which provides an additional 
platform for drug targets identification and insights on their role in the 
metabolic networks.  
While re-recognizing metabolic adaptation as a factor of Mtb pathogenesis in 
recent years, TB researchers have also adopted the metabolomics approach, in 
which metabolites produced by Mtb are determined using mass spectrometry 
to create a metabolite profile (Brauer et al., 2006). Analysis of the carbon 
metabolic profiles of in vitro and ex vivo revealed that Mtb could catabolize 
multiple carbon sources simultaneously, with each carbon source differently 
catabolised via respective pathways to distinct metabolic fates, to achieve 
enhanced monophasic growth (de Carvalho et al., 2010). It is also of interest 
to understand the lipid profile of Mtb given the virulence role that 
mycobacterial lipids play during intracellular survival. Methods of 
comparative lipidomics have been adopted to survey the lipid changes in the 
mycobacterial cell walls during an infection or among clinical isolates of 
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mycobacteria, and identified strain specific-molecules that could be used as 
biomarkers (Layre et al., 2011).  
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1.3. Survival mechanisms of Mtb within the host  
Part of the first line of cellular defense against microbial invasion, the 
macrophage represents the main host cell for Mtb persistence and survival. 
The macrophage infection model has hence become an essential model in TB 
research for elucidating mechanisms of the bacilli intracellular survival, in 
complementation to the in vivo animal models. In addition, several factors of 
persistence have been associated with the activation status of the macrophage 
(resting versus activated), the metabolism of Mtb during intracellular 
persistence, and its extra-phagosomal or non-macrophage cell occupancy. 
1.3.1. Intra-phagosomal survival within the macrophage 
1.3.1.1. Survival mechanisms within a resting macrophage. 
One of the main strategies for Mtb to survive and replicate within the resting 
macrophage is to arrest the phagosomal maturation by inhibiting fusion of an 
Mtb phagosome with lysosomes (Figure 1.5), a hostile acidic environment 
which contains bactericidal components such as hydrolyases and cationic 
peptides. Mtb thus remains in a vacuole that has the characteristics of an early 
endosome with access to nutrients through the endosomal recycling pathway 
(Russell, 2001). In this sub-cellular environment, Mtb replicates actively and 
avoids lysosomal processing, thereby limiting killing and host adaptive 
immune responses through antigen presentation (Russell, 2001). Several 
mycobacterial factors have been implicated in the phagosome maturation 
arrest and these include the mycobacterial cell wall component 
lipoarabinomannan (LAM) (Fratti et al., 2003), the serine/threonine protein 
kinase G (PknG) (Walburger et al., 2004),  the secreted acid phosphatase M 
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(SapM) (Vergne et al., 2005), the rv3377-78c locus (Pethe et al., 2004), and 
the secreted protein-tyrosine phosphatase A (PtpA) (Bach et al., 2008). These 
factors were shown to mainly interfere with intracellular trafficking events 
essential for phagosome-lysosome fusion and acidification, for instance, the 
acquisition of the early endosomal antigen 1 (EEA1) (Fratti et al., 2003), the 
trafficking of V-ATPase to phagosome for proton influx (Wong et al., 2011),  
Ca2+/calmodulin-dependent signalling pathways (Vergne et al., 2003), and 
cytoskeletal dynamics (actin) (Anes et al., 2003) within the host macrophage.  
Besides inhibition of phagosome-lysosome fusion, Mtb was reported to inhibit 
apoptosis of infected macrophages with low multiplicity of infection 
(Durrbaum-Landmann et al., 1996) and with LAM (Roach et al., 1993) 
possibly inducing TNF- production by the infected cell, which prevents 
apoptosis. This prolonged survival of the infected cell can be advantageous for 
intracellular survival given the extended time for Mtb to replicate inside the 
host cell.  
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1.3.1.2. Survival mechanisms within an activated macrophage.  
The capacity of Mtb to block its trafficking to the lysosomal compartment is 
limited to resting macrophages. On the contrary, mycobacteria are confronted 
with a whole new and more hostile environment when the macrophage is 
activated. Activation of macrophages by IFN-, ATP or selected 
mycobacterial lipids allows the phagosomes to mature by fusion with the 
lysosomes, thereby translocating mycobacteria into a phagolysosomal 
compartment (Figure 1.5). The lysosomes bring along an array of digestive 
enzymes such as lipases, proteases, nucleases, amylase, and other bactericidal 
components such as phosphoric acid and cationic peptides, leading to the 
killing of the great majority of the bacilli in this compartment. Nonetheless, a 
small proportion is believed to remain alive, and capable of surviving within 
this acidic (pH5.5), highly nitro-oxidative, nutrient-limiting and possibly 
hypoxic compartment (MacMicking et al., 2003; Schaible et al., 1998). Indeed, 
the ability to persist within the activated macrophage is independent of the 
ability to inhibit phagosome maturation, as evidently shown when Pethe and 
colleagues isolated mutants that lacked the ability to block the phagosome 
maturation in resting macrophages, and trafficked into the phagolysosomes of 
activated macrophages (Pethe et al., 2004). Specifically, a range of 
mycobacterial genes has been identified to be involved in  the detoxification of 
RNI and ROI, and in protein and DNA repair and protection within the 
phagolysosomal compartment (Ehrt & Schnappinger, 2009). Genes related to 
cell wall functions were also associated with increased acid sensitivity of Mtb 
upon deletion, indicating that maintaining an intact mycobacterial cell wall is a 
form of acid resistance in Mtb. Moreover, a (limited) number of genes have 
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been identified to be specifically involved in Mtb survival within activated 
macrophages. Rv3671c, a gene encoding for a membrane-associated serine 
protease was recently found to be largely responsible for Mtb to resist acid and 
maintain intra-bacterial pH under in vitro acidic conditions and in activated 
macrophages (Vandal et al., 2008b). Deletion of the acid and phagosomal 
regulated (aprABC) locus abolished the survival of Mtb within resting and 
activated macrophages (Abramovitch et al., 2011).  Previous work also 
described that the absence of a key enzyme of the glyoxylate shunt, isocitrate 
lyase (ICL), leads to an attenuated phenotype in IFN-activated macrophages 
and in mice (Munoz-Elias & McKinney, 2005), suggesting a critical role of 
the central metabolism in intracellular persistence, in particular the ability to 
metabolize host-derived lipids.  
At the transcriptome level, microarray studies in resting versus activated 
macrophages have highlighted the differential physiological status of 
pathogenic mycobacteria in both types of macrophages (Schnappinger et al., 
2003). More interestingly, it was found that Mtb isolated from activated 
macrophages displayed the genetic signatures of a non-replicating latent 
bacillus, affirming the crucial role of activated macrophages in Mtb 
persistence. 
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1.3.2. Metabolic versatility of Mtb 
The in vivo metabolism of Mtb has emerged to be a key factor in its 
persistence. It is therefore of great urgency to comprehend the extensive in 
vivo metabolic requirements for sustaining habitation within its host, to 
develop therapeutic strategies that effectively eliminate the ancient pathogen 
successfully. Here, we summarize the most recent knowledge on the carbon, 
nitrogen and other sources that are being utilized by Mtb for in vitro growth 
and in vivo persistence.  
1.3.2.1. Carbon sources 
Being metabolically versatile, Mtb is able to assimilate a variety of carbon 
sources derived from carbohydrates, fatty acids, tricarboxylic acid (TCA) 
cycle intermediates, carbon backbone of amino acids, to even host lipids 
(Cook et al., 2009). While glycerol is the preferred carbon source for 
mycobacterial growth in vitro, it is also able to utilize glucose efficiently 
(Ratledge, 1976). Through the activities of glucokinases, ppgK and glkA, Mtb 
is able to access glucose in vivo during chronic mouse infection, which 
contributed critically to the persistence of Mtb in mice (Marrero et al., 2013).  
On the contrary, several studies indicated that there is a switch of preference 
for the pathogen to assimilate fatty acids instead of carbohydrates during the 
course of infection. The sequencing of the Mtb genome had revealed an ‘over-
representation’ of genes involved in lipid degradation, with a considerable 
number being extensively duplicated (Cole et al., 1998), empowering Mtb 
with the ability to metabolize lipids. Moreover, genes involved in the 
biochemical activation and -oxidation of fatty acids were unanimously 
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identified to be up-regulated in  microarray studies on the Mtb transcriptome 
during in vitro growth with regulated parameters (nutrients, oxygen, pH) 
(Betts et al., 2002; Hampshire et al., 2004), during macrophage infection 
(Fontan et al., 2008; Schnappinger et al., 2003) and during mouse infection 
(Timm et al., 2003). Of which, icl1 and icl2 contribute to the total ICL activity 
to drive the glyoxylate cycle in Mtb, which is essential for anaplerosis during 
fatty acid catabolism (Munoz-Elias & McKinney, 2005). ICL1 also possesses 
2-methylisocitrate lyase (MCL) activity, which is critical for a functional 2-
methylcitrate acid cycle (Gould et al., 2006) to break down toxic propionyl-
CoA (Yang et al., 2009) arising from the metabolism of cholesterol, and 
methyl-branched fatty acids and amino acids, and odd-chain-length fatty acids 
(Munoz-Elias et al., 2006). The deletion of both icl1 and icl2 genes has 
rendered Mtb incapable of establishing infection in mice, thereby highlighting 
the importance of fatty acid metabolism for its in vivo persistence. Cholesterol 
is also a convenient source of energy for Mtb persistence, given its abundant 
presence in humans, be it a major component of cell membranes or as a 
precursor of steroidal sex hormones. It has been clearly demonstrated that Mtb 
utilizes cholesterol for the synthesis of phthiocerol dimycocerosate (PDIM) 
(Lee et al., 2013), and that its acquisition is likely via the Mce4 transporter 
(Mohn et al., 2008), given that the mce4 mutant was unable to sustain 
chronic persistence in mouse lungs and in IFN- stimulated macrophages 
(Pandey & Sassetti, 2008). Studies have also identified choD (Brzostek et al., 
2007) and hsaC (Yam et al., 2009), which encode for key enzymes in the 
cholesterol catabolism pathway, to be important for Mtb persistence, whereby 
their respective deletions impaired the replicative ability of Mtb within 
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macrophages and the lungs from mice and guinea pigs. The attenuated in vivo 
phenotype was also observed in Mtb deleted for the igr operon, which 
contains genes that are homologous to a Rhodococcus cholesterol-catabolic 
locus (Chang et al., 2009).  
Ensuring a smooth catabolic flow through the pathway in which the energy 
sources are assimilated is also crucial to the viability of the bacilli, probably to 
prevent the accumulation of toxic metabolites within the bacilli. This notion 
has been supported by the finding that the in vivo growth defect of Mtb igr 
was restored upon deletion of mce4 operon, indicating that cholesterol uptake 
can be detrimental to Mtb if it is deficient in the relevant catabolizing enzymes. 
On a similar note, our laboratory recently discovered that phosphofructokinase 
activity (PFKA) in Mtb contributes essentially in maintaining a glycolytic 
carbon flow during glucose metabolism under in vitro hypoxic conditions 
(Phong et al., 2013) to prevent the accumulation of sugar phosphates, which 
are toxic to Mtb (Pethe et al., 2010).  
Mtb also induces a physiological change at the site of infection which also 
suggested a predisposition to lipid metabolism. Studies have showed that 
oxygenated mycolic acids, exclusively produced by pathogenic mycobacteria, 
induce the accumulation of lipid bodies in infected macrophages, forming 
foamy macrophages (FMs) (D'Avila et al., 2006; Peyron et al., 2008).  The 
lipid bodies are products of dysregulated lipid metabolism, in which 
cholesterol is esterified and sequestered in intracellular droplets that form in 
the endothelial reticulum and accumulate within the cell cytosol (Galkina & 
Ley, 2009). Electron microscopic analysis has suggested that Mtb can gain 
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physical access to the lipid droplets within the cell (Peyron et al., 2008). The 
presence of FMs in TB granulomas (Ordway et al., 2005) further supports the 
notion that TB granuloma is a privileged site to sustain persistent bacteria by 
providing nutrients, and FMs can be an ideal host cell that is anergic to 
activating cytokines.  
Finally, the versatility of Mtb in metabolism was recently demonstrated in two 
key carbon metabolomics studies, which revealed that Mtb co-catabolizes 
multiple carbon sources simultaneously (Beste et al., 2013; de Carvalho et al., 
2010). Mtb might have evolved to optimize intracellular carbon flux so as to 
persist within diverse environmental conditions.  
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1.3.2.2. Nitrogen sources 
Mtb prefers amino acids, particularly asparagine, glutamate and aspartate, as 
the nitrogen source for in vitro growth. In the absence of these amino acids, it 
is able to assimilate inorganic sources, such as ammonium salts (Ratledge, 
1976) for biosynthesis of L-glutamine and L-glutamate, where the balance of 
both amino acids is critical for the pathogen’s survival, since L-glutamine is a 
major component of the cell wall, both in the form of D-isoglutamine in the 
peptidoglycan, and as the major cell wall component poly-L-glutamine.  
However, the uptake of ammonium remains unknown in Mtb, although it 
expresses aMtb, a putative ammonium uptake system which has been 
functionally characterized in actinomycetes (Strosser et al., 2004). Like most 
bacteria, Mtb assimilates ammonium via glutamine synthetase (GS), the gene 
product of glnA1, which was shown to be essential for Mtb growth in human 
THP-1 macrophages and guinea pigs (Tullius et al., 2003). Furthermore, the 
promoter of  essential glnE gene product adenylyltransferase (Parish & Stoker, 
2000a), which controls the activity of Mtb GS through adenylylation (Fink et 
al., 1999), is found to be up-regulated by  ammonia/glutamine-containing 
media (Pashley et al., 2006), indicating the importance of 
glutamine/ammonium assimilation for in vivo survival of Mtb. Similarly, it is 
critical for Mtb to be able to synthesize several essential amino acids, such as 
leucine, proline, tryptophan and glutamine, for its intracellular survival within 
macrophages (Hondalus et al., 2000; Smith et al., 2001). On the other hand, 
some Mtb auxotrophic mutants of methionine, isoleucine and valine can 
successfully proliferate in the macrophages (Awasthy et al., 2009b; McAdam 
et al., 1995), which suggests a possibility that other amino acids can be 
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acquired from the macrophages by Mtb. This is further supported by a recent 
metabolomics analysis on metabolic interactions between Mtb and its host 
macrophage whereby macrophage amino acids alanine, glutamate/glutamine 
and asparagine/aspartate were found to be assimilated by Mtb (Beste et al., 
2013). Hypoxic mycobacteria was also reported to utilize exogenous nitrate as 
an efficient terminal electron acceptor (TEA) to generate energy, which allow 
them to resist in vitro acidity and nitric oxide (NO) stress (Tan et al., 2010).  
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1.3.2.3. Iron and magnesium  
Metals such as iron and magnesium are essential for the survival of 
prokaryotes, as part of prosthetic groups or co-factors in many enzymes of key 
metabolic processes. Key studies have clearly demonstrated iron as an 
essential requirement for the virulence of Mtb. Mtb has been described to 
acquire iron within an iron-limiting environment of the macrophage via the 
production of iron-chelating siderophores, mycobactin and carboxymycobatin. 
The biosynthesis machinery of the siderophores is encoded by the Mtb cluster, 
which includes genes mbtA to mbtJ. Indeed, a mutation in any mbt gene has 
led to a growth defect of Mtb in iron-limited medium and THP-1 macrophages 
(De Voss et al., 2000). In addition, the functional export of synthesized 
siderophores via MmpS4/MmpL4 and MmpS5/MmpL5 efflux system (Wells 
et al., 2013), and the uptake of Fe3+-siderophore complex proposed through 
the IrtAB transport (Rodriguez & Smith, 2006), have been described to be 
critical in the successful utilization of iron by Mtb to exert its virulence. 
Similarly, magnesium, an essential co-factor for enzymes binding to 
phosphate and nucleic acid synthesis, was described to be taken up by MgtC, a 
transmembrane P-type ATPase protein. Mtb was unable to proliferate in 
human macrophages and lungs and spleens of mice when mgtC was deleted 
(Buchmeier et al., 2000). 
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1.3.3. Extra-phagosomal and non-macrophage intracellular survival  
The association of the tubercule bacilli with phagosome is always observed in 
all studies using human and mouse macrophages, as well as granulomatous 
tissue from infected animals and TB patients, thereby firmly supporting the 
notion that Mtb persists within these membrane vesicles of the macrophage. 
On the contrary, the possibility that Mtb could also exist intracellularly outside 
the phagosomes was raised when cytoplasmic bacilli was discovered by van 
der Wel and colleagues, several days post-infection (van der Wel et al., 2007). 
It was hence proposed that Mtb possesses the ability to escape out of the 
phagolysosome into the cytosol, thus gaining access to nutrients present in the 
cytoplasmic compartment (Figure 1.5).  Using immunogold labeling and 
electron microscopy, they further showed that the translocation from the 
phagolysosome to the cytosol is dependent on the ESX-1 mediated ESAT-6 
secretion system (Houben et al., 2012), an immunogenic cluster encoded 
within the region of difference 1 (RD-1) genomic region which has been well-
studied for its role in plasma membrane lysis (Gao et al., 2004; Guinn et al., 
2004; Junqueira-Kipnis et al., 2006; Koo et al., 2008). The RD-1 region has 
also been implicated to induce necrosis of human neutrophils in a ROS-
dependent manner thus preventing the killing of Mtb (Corleis et al., 2012). 
Furthermore, with 15% of reactivating cases occurring at extrapulmonary sites 
without active pulmonary TB, it is likely that non-macrophage cells could 
harbor persisting Mtb and subsequently lead to reactivation. Consistently, Mtb 
DNA could be detected in the fat tissue, liver, spleens and kidneys (Barrios-
Payan et al., 2012) from patients who had died from causes other than TB. 
Neyrolles and colleagues also showed that Mtb can be taken up by adipocytes 
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through the scavenger receptors and subsequently survive in a non-replicating 
state (Neyrolles et al., 2006) within the adipocytes. This observation is also in 
line with the metabolic switch to lipids during intracellular persistence of the 
bacilli. Given the abundance and wide distribution of adipose tissue 
throughout the body, adipocytes thus represent a vast reservoir for persisting 
Mtb and could potentially provide a new model of dormancy.    
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1.4. Specific aims of study 
Limited knowledge on the pathogenesis of Mtb, especially during the latent 
form of the disease, forms the bottleneck in the discovery of new anti-
tubercular drugs and vaccines. Years of research have revealed that Mtb is a 
vastly adaptive organism that employs self defense tactics to either sustain 
within differing micro-environments, or circumvent host immune responses to 
prolong its residency within the host, and there is definitely more to this range 
of armor than meets the eye. Therefore, this thesis aims to unravel novel 
mechanisms that empower the bacilli to survive within their host. Specifically, 
we postulate that instead of a dead end, the phagolysosomal compartment of 
activated macrophages may represent a reservoir for latent mycobacteria. Thus, 
we propose to identify (some of) the mechanisms that are involved in Mtb 
survival within the lysosomal compartment, and have chosen two 
mycobacterial factors, urease and rv1258c, based on the following rationale: 
1) Ureases catalyze the breakdown of urea to ammonia, which has been well-
described as a virulence factor of numerous bacterial pathogens. Mtb also 
expresses urease, whose substrate was also found to be specific for urea 
(Clemens et al., 1995). We therefore propose that Mtb could utilize urea 
generated by the host cells to produce ammonia, which would neutralize the 
acidic intra-phagosomal environment and act as a nitrogen source, and hence 
sustaining its intracellular survival.  
2) The ability to survive within the phagolysosomal compartment of activated 
macrophages is unlikely to rely on a single bacterial factor. We hence propose 
that a specific set of genes or programme in Mtb may be triggered when the 
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mycobacteria-containing vacuole fuses with the lysosomal compartment upon 
macrophage activation, to allow Mtb to persist inside its host. Exploiting on 
the mycobactericidal property of the lysosomal soluble fraction (SF), prepared 
from activated macrophages (Alonso et al., 2007), we describe a novel in vitro 
lysosomal exposure model to identify new mechanisms that are specifically 
triggered in Mtb upon contact with the phagolysosomal contents. Next 
generation sequencing was performed to profile the Mtb transcriptome, and 
RNA-Seq data analysis revealed that Mtb does respond to the lysosomal 
environment through the differential expression of a massive number of 
mycobacterial genes. There is also an enrichment of genes encoding for 
mycobacterial transporters during in vitro lysosomal exposure. Of particular 
interest, and in order to validate the relevance of our in vitro lysosomal 
exposure model, we selected rv1258c, an Mtb transporter described with an 
efflux pump activity. We hypothesized that the efflux action of the pump 
could be involved in extruding anti-microbial agents present within the 
lysosomes, thus improving the viability of intracellular Mtb.  
The literature background specific for each section will be presented in their 





Chapter 2: Materials and Methods 
 
All the experiments involving live Mycobacterium tuberculosis were 
performed in a BSL3 laboratory following Standard Operating 
Procedures (SOPs) approved by the Institutional Bio-safety Committees 
(IBC) from Defense Science Organization (DSO) National Laboratories 
and National University of Singapore (NUS).  
 




2.1.1. Bacterial strains 
All E. coli and Mtb strains used or constructed in this study are listed in Table 
2.1. The chemically competent E. coli TOP10 strain was used for propagation 
of all plasmids in this study while the mycobacterial mutants were 
constructed in the Mtb CDC1551 background.  
Strain Feature Source 
TOP10 Chemically competent E.coli  Invitrogen 
CDC 1551 Mtb wild type ATCC 
hygureC Mtb CDC1551 electroporated with pYUB854-ureC This study 
ureC Mtb CDC1551 ureC::hyg electroporated with 
pWM19 
This study 
1258c Mtb CDC1551 electroporated with pYUB854-rv1258c This study 
Compl-ure Mtb CDC1551 ureC electroporated with pMV306-
ureABC 
This study 




Table 2.1: List of bacterial strains used in this study. 
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2.1.2. E. coli growth conditions 
All E. coli strains were grown in Luria-Bertani (LB) broth and agar (Difco). 
When appropriate, hygromycin and kanamycin were added at 150 and 50 
g/ml into the medium, respectively. 
 
2.1.3. Mtb growth conditions  
Mycobacteria were grown in Middlebrook 7H9 medium (Difco), or in Dubos 
medium (Difco), or on Middlebrook 7H11 agar containing cycloheximide 
(100 g/ml), when necessary. When appropriate, hygromycin, kanamycin, 
gentamicin and X-gal were respectively added at 80, 20, 10 and 40 g/ml.  
To study the source of nitrogen utilized by Mtb, mycobacteria were grown in 
an in-house minimal medium (See Appendix 1). Glutamate, urea or 
ammonium sulphate (Sigma-Aldrich) was added to the minimal medium at the 
indicated concentrations, when appropriate. Mycobacterial cells were first 
grown in Middlebrook 7H9 medium to mid-log phase and washed once with 
the minimal medium to remove any residual 7H9 medium. The washed 
bacterial pellet was carefully resuspended in minimal medium and used to 
inoculate 10 ml of minimal medium supplemented with the desired nitrogen 
source at an initial optical density at 600nm of 0.05 (OD600 0.05) in a T25 flask 
(Nunc Flasks Nunclon™Δ with Filter Cap). The flasks were incubated at 37 
C up to 10 days. Readings at OD600 were performed every 2 days. Growth 
was scored positive when OD600 read-out was 0.05 or higher. 
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2.2. Molecular Biology 
2.2.1. Plasmids and primers 
All plasmids constructed for this study are listed in Table 2.2, while all 
primers designed for this study are listed in Table 2.3. All Mtb gene–related 
primers were designed based on the sequences obtained from Comprehensive 
Microbial Resource (http://cmr.jcvi.org/tigr-
scripts/CMR/shared/Genomes.cgi). Where necessary, restriction enzyme sites 
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Plasmid name Feature Source 
General plasmids 
pCR2.1 TA cloning vector Invitrogen 
pYUB854 Empty cosmid vector with two MCS sites 
flanking the res-hyg-res cassette, hyg 
Bardarov et al, 
2002 
pGOAL17 Carrier vector containing PAg85-lacZ and 
Phsp60-sacB PacI cassette, amp 
Parish and 
Stoker, 2000 
pWM19 Thermo-sensitive vector expressing-
resolvase (tnpR), hyg and gm 
Malaga et al, 
2003 
pMV262 E. coli-mycobacteria shuttle vector with 
Phsp60 upstream of MCS, kan 
Stover et al, 
1991 
pMV306 Integrative E.coli-mycobacteria vector 
carrying attP site, integrase (int) gene, and 
MCS, kan  
Stover et al, 
1991 
Plasmids for knock-out mutant construction 
pYUB854-urec Final cosmid vector containing flanking 
homologous regions of ureC, and PAg85-




Final cosmid vector containing flanking 
homologous regions of rv1258c,and 
PAg85-lacZ and Phsp60-sacB PacI 
cassette, hyg 
This study 
Plasmids for complementation 
pMV306-ureABC pMV306 containing ureABCunder Pure, 
kan 
This study 
pMV306-rv1258c pMV306 containing rv1258c under 




pMV306 containing rv1258c under 
Phsp60, kan 
This study 
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Primers used to amplify 5’ and 3’ PCR fragments for pYUB854 cloning  















Primers used for PCR screening of knock-out mutants. 
Gene Sequence (5’-3’) 












hyg F: ACTGCTTGTCCGATATCTGAT 
R: GAACTGGCGCAGTTCCTCT 
  
Primers used for amplifying mycobacterial genes with their respective native 
promoter. 
Gene Sequence (5’-3’) 
ureABC F: TTTCTAGAACAACGCTTCGTGGACTTGG 
R: TTAAGCTTAGAACAGGAAATACCGTTGTG 
rv1258c F: TTTCTAGATTGAGTTCGCAGATCGAGCCA 
R: AAGCTTCACTGAGCCGATCCTACGG 
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Primers used for probe synthesis for Southern blot hybridization. 
Probe Sequence (5’-3’) 
ureC F: CGCACCGTCGCAGAGTTGAT 
R: GTATCCGGTCGCCGGTGGTA 
rv1258c F: GGCGATTGTGAATCTGGTGA 
R: CCGAAAACGGTGCGATAGAC 
hyg F: TTGTCCGCTTCCACTGCGCCC 
R: TTGGAGGCGTACGCGGTCCTG 
 
Primers used for real time PCR. 
Gene Sequence (5’-3’) 
ureA F: ATGGAGGGAGTGCCGGAGAT  
R: GACGTGGCTACCGACCTGCA 
ureC F: GTCACCGAAGACCGGTGTGG 
R: ATCCCGATGTCGGCCTTGAT 
ureF F: CCCTGGAAGCGTTCCTGAAAC 
R: GTTCCTCCCAGCCGGAATCG 
rv1258c F: GGGCAGCATCGAGTCACGAG 
R: GACCATGCTGCCGCTGTTGTT 
rv1257c F: CTCGCTGCCGACGAACAGTTT 
R: GCCTGTACAACGCCGAGGTG 
sigA F: GCGACCAAAGCAAGCACGGC 
R: GTCGTAGTGTCCTGGGGTGC 
 
Table 2.3: List of primers designed for this study.  
Restriction enzyme sites are underlined. 
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2.2.2. Polymerase Chain Reaction (PCR) 
All PCR reactions were prepared with the GoTaq® Colorless/Green Master 
Mix Product (Promega), and carried out using the Biorad iCycler. The PCR 
reaction mix was set up as below: 
Component Volume (l) 
5x GoTaq® Colourless reaction Buffer 5 
dNTP mix (10mM) 1 
Upstream and downstream primers (10mM) 5 
GoTaq® DNA polymerase (5U/ul) 0.25 
Template DNA (100-500ng) 1  
Nuclease free water 37.75 
Total volume 50 
 
The cycling conditions for the reaction mix were ran as shown below: 
Step Temperature Time Number of cycles 
Initial Denaturation 95ºC 2 minutes 1 
Denaturation 95ºC 50 seconds 
25-30 Annealing Refer to Table 45 seconds 
Extension 72ºC 1kb/minute 
Final extension 72ºC 7 minutes 1 
Hold 10ºC Infinite 1 
 
The PCR products were visualised on a 1% agarose gel after DNA gel 
electrophoresis. 
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2.2.3. Restriction enzyme digestion 
Plasmid DNA was digested with the indicated restriction enzymes (RE) in 
their corresponding buffers (New England Biolabs, Ipswich, MA) according to 
the manufacturer’s protocol. Analysis of the digested profile was performed 
by DNA gel electrophoresis (Section 2.2.5.1). 
2.2.4. Sub-cloning 
PCR fragments were cloned into the TOPO® vector using the TOPO® TA 
Cloning Kit (Invitrogen, Carlsbad, CA) according to manufacturer’s protocol. 
Sequencing was carried out to select for the TOPO® vector carrying the 
correctly amplified PCR sequence. Digestion (Section 2.2.3) with the 
appropriate RE(s) was performed to linearise the destination vectors and 
excise the inserts from their TOPO® vectors. Both digested vectors and inserts 
were purified by gel extraction (Section 2.2.5.2). The inserts were ligated to 
their destination vectors using the DNA Ligation Kit Mighty Mix (Takara) 
according to the manufacturer’s recommendations.  
 
Chapter 2: Materials and methods 
60 
 
2.2.5. Agarose gel electrophoresis 
2.2.5.1. Sample migration 
DNA or RNA samples were resolved on 1.0% to 1.5% agarose in 
1xTrisacetate (TAE) running buffer (0.04 M Tris-acetate and 0.001 M 
ethylenedinitrilotetra acetic acid (EDTA), pH 7.8). Each sample was mixed 
with 1/5 volume of 6x loading dye (0.25% bromophenol blue, 0.25% xylene 
cyano land 25% Ficoll in water) and loaded into the gel wells. Five µl of 1kb 
or 100 bp DNA ladder (Promega) were used as markers for estimation of band 
size. Electrophoresis was carried out at 100 V for 1 h, after which the gel was 
stained in 0.5g/ml of ethidium bromide solution (Invitrogen) for 15 min 
before viewing under a ultra-violet (UV) transilluminator (ChemiGenius, 
Syngene, UK). 
2.2.5.2. Gel extraction 
Following agarose gel electrophoresis, the DNA fragments of interest were 
excised under low UV light (366 nm) to prevent DNA damage, and extracted 
using the QIAquick Gel Extraction (Qiagen) according to the manufacturer’s 
protocol. 
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2.2.6. E. coli transformation 
Chemically competent One Shot® TOP10 E. coli (Invitrogen) were 
transformed with slight modifications to manufacturer’s protocol. Half volume 
of ligation mix was added to one vial of TOP10 cells and mixed gently. The 
tube was cooled on ice for 30 min, followed by an immediate transfer to 42ºC 
for 45 s. LB medium (500 µl) was added immediately to the heat-shocked 
cells. After incubation at 37ºC for 1 hour, 100 μl of transformation mixture 
were plated on imMediaTM Amp Blue ready-mix agar (Invitrogen) for 
blue/white screening or LB agar supplemented with the appropriate antibiotic. 
The plates were incubated at 37ºC overnight. 
2.2.7. DNA sequencing 
Plasmids from the recombinant clones were sent for DNA sequencing (AIT 
Biotech, Singapore) with the appropriate primers. The obtained sequences 
were aligned to the reference sequence using the Basic Local Alignment 
Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
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2.2.8. Construction of knock-out mutant and complemented strains 
2.2.8.1. Disruption of mycobacterial genes 
Disruption of the mycobacterial genes was performed via allelic exchange 
(homologous recombination) as previously described (Bardarov et al., 2002). 
Figure 2.1 illustrates the homologous recombination between the flanking 
regions (5’ PCR and 3’ PCR) resulting in the replacement of the gene of 
interest by the hygromycin resistance cassette from pYUB854 plasmid. 
Figure 2.1: Gene disruption via allelic exchange.  
 
2.2.8.2. Construction of knock-out plasmids and mutant strains 
A pYUB854 plasmid was constructed for each gene of interest. 5’ and 3’ PCR 
fragments of 0.9 - 1 kb, which flank the open reading frame (ORF) to be 
deleted, were amplified from Mtb CDC1551 wild type genomic DNA using 
the primers listed in Table 2.3, and sub-cloned sequentially into the pYUB854 
plasmid (Section 2.2.4) using the corresponding restriction sites present in the 
multiple cloning sites (MCS) flanking the hygromycin resistance gene hyg. 
PacI-restricted fragment containing the selection genes lacZ and sacB was 
excised from pGOAL17 (Parish & Stoker, 2000b) and ligated into the 
Chapter 2: Materials and methods 
63 
 
pYUB854-PCR5’-3’ construct to give the final delivery vector pYUB854-
(gene). The plasmids were electroporated as described in Section 2.2.8.5. The 
transformants were plated on 7H11 plates containing hygromycin and X-gal 
(Bio-Rad). White and hygromycin-resistant colonies were selected after 3 
weeks of incubation. For each gene, the deletion at the correct locus was 
verified by PCR using sets of primers to amplify the hygromycin cassette, the 
deleted region, and the regions that flanked the deleted region (Table 2.3), and 
by Southern blot analysis (Section 2.2.10). 
2.2.8.3. Construction of complementation vector of mycobacterial 
genes, and complemented strains 
Complementation of the Mtb knock-out mutants was performed by 
introducing the genes into the genomes of the respective mutant strains using a 
promoter-less integrative plasmid, pMV306 (Stover et al., 1991). The plasmid 
carries a DNA segment containing the attachment site (attP), integrase (int) 
gene from the mycobcateriophage L5 and a Tn903-dereived aph gene, which 
permits site-specific integration at the chromosomal attB site in mycobacteria 
and subsequent selection on kanamycin-containing agar plates for successful 
integration. The ORFs of interest were amplified from Mtb CDC1551 wild 
type genomic DNA, either with or without their native promoter. In the latter 
case, the mycobacterial hsp60 promoter excised from the pMV262 plasmid 
(see Appendix) and cloned in front of the MCS. The respective PCR products 
were amplified using primers listed in Table 2.3, cloned into TOPO vector for 
sequencing and finally sub-cloned into pMV306 to give the final delivery 
vector pMV306-(gene), as listed in Table 2.2. The plasmids were 
electroporated as described in Section 2.2.8.5. Kanamycin-resistant colonies 
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were picked for further screening. For complemented ureC mutant, the 
successful clones were confirmed through displaying phenotypic growth in 
minimal medium with 3.5mM urea. For complemented rv1258c mutant, real 
time PCR was performed to select for clones expressing the gene of interest. 
2.2.8.4. Construction of unmarked mutant strains 
Generation of an unmarked mutant strain involves the excision of the 
hygromycin resistance cassette from the genome of the marked mutant strain. 
This is carried out by a restriction enzyme,-resolvase, which cleaves 
specifically at the res sites (Figure 2.1) flanking the hygromycin cassette. The 
mutant strain was transformed with the thermo-sensitive plasmid pWM19, 
encoding the -resolvase (tnpR) (Bardarov et al., 2002), as described in 
Section 2.2.8.5. Gentamycin resistant colonies were first selected after 
incubation at 31C for the resolvase activity, and selected again on 7H11 
containing 2% sucrose after incubation at 39C, a non-permissive temperature 
for pWM19 replication. The colonies were screened by PCR for the absence 
of the hygromycin resistance cassette using primers listed in Table 2.3. 
 
2.2.8.5. Electroporation and selection of transformants 
The mycobacterial cultures (50 ml) were grown in 7H9 medium without 
glycerol to mid-log phase (OD600 0.6-0.8) and supplemented with 0.1% 
glycine 16 hours one day prior to electroporation. To prepare for 
electroporation, the cells were washed with equal volumes of 0.05% Tween-80 
for three times and resuspended in the same wash buffer to the OD600 40. The 
pYUB854 plasmids were subjected to 70 mJ/cm2 of UV-irradiation prior to 
electroporation. At least 1ug of plasmid was electroporated into the electro-
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competent bacterial cells in a cuvette with a 2mm electrode gap (Bio-Rad). 
The electroporation was carried out at 2500V, 25µF capacitance and 800-
100Ω resistance in a Gene Pulser Xcell machine (Bio-Rad). The 
electroporated bacterial suspension was recovered in 7H9 medium at 37°C 
overnight before plating on 7H11 plates containing the respective antibiotics 
for selection. Successful transformants were observed as colonies after 3 
weeks of incubation. Further screening was performed as described in 
previous sections of mutant strain construction.  
2.2.9. Mycobacterial genomic DNA isolation 
Mycobacterial culture was grown to late-log phase (> OD600 1) in 50 ml 7H9 
medium and was harvested by centrifugation at 4,000 rpm for 10 minutes. The 
bacterial pellet was washed with 0.05% Tween 80 and re-suspended in 600 μl 
Buffer 1 containing 3% SDS, 1 mM CaCl2, 10 mM Tris-HCl, and 100 mM 
NaCl. The suspension was heat-inactivated at 95°C for 20 minutes, followed 
by centrifugation at 13,000 rpm for 10 minutes to pellet cell debris. EDTA 
was added to the supernatant, at a final concentration of 2 mM. An equal 
volume of phenol/chloroform/isoamylalcohol (49:49:2, v/v/v, Sigma-Aldrich) 
was then added to the sample, and mixed vigorously for 1 minute in a phase-
lock tube (Eppendorf). The aqueous phase was extracted upon centrifugation 
at 13,000 rpm for 5 minutes. 0.1 volume of 3 M sodium acetate and 0.8 
volume of isopropanol were then added to the aqueous phase to precipitate 
DNA. The DNA pellet was obtained by centrifugation at 13,000 rpm for 15 
minutes, and washed with 500 μl of 70% ethanol. The pellet was air dried and 
was dissolved in the desired volume of TE buffer containing 10 mM Tris pH 
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8.0 and 0.2 mM EDTA. The genomic DNA was stored at -20°C for long-term 
storage. 
2.2.10. Southern Blot analysis 
2.2.10.1. Synthesis of DIG-labeled probes 
The probes were synthesized using the PCR Digoxigenin (DIG) Probe 
Synthesis Kit (Roche) using the primers listed in Table 2.3, with slight 
modifications.  




5x GoTaq® Colourless reaction Buffer 5 5 
dNTP mix (10mM) 3.5 5 
DIG-UTPs 1.5 0 
Upstream and downstream primers (10mM) 5 5 
GoTaq® DNA polymerase (5U/ul) 0.25 0.25 
Template DNA (100-500ng) 1  1 
Nuclease free water 38.75 38.75 
Total volume 50 50 
 
GoTaq® DNA polymerase (Promega) and its cycling conditions were used 
(Section 2.2.2). A control mix in which DIG-UTPs were omitted was also 
prepared. As DIG-labelling rendered the probes heavier in molecular weight, 
successfully labelled probes were resolved as a higher band compared to the 
unlabelled probes on a 1% agarose gel. To prepare for hybridization, the 
probes were denatured at 95C for 5 minutes and placed on ice immediately to 
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2.2.10.2. Transfer of genomic DNA from agarose gel to membrane 
Restriction digestion of at least 1g of genomic DNA isolated from Mtb wild 
type (WT) and mutant strains using relevant REs was carried out at 37 °C for 
4 hours before resolving on a 1.5% agarose gel. The resolved genomic DNA 
was subsequently depurinated, denatured and finally neutralised by treating 
the gel with two washes of depurination, denaturation and neutralisation 
solutions (see Appendix for composition) each in this sequence, with constant 
gentle agitation. A sizable piece of positively charged nylon membrane 
(Millipore) was equilibrated in the neutralising buffer before the assembly of 
the transfer setup. The transfer setup was assembled starting with the gel as the 
most bottom layer, followed by the equilibrated nylon membrane, filter paper 
(Whatman), paper towels and finally weights (Figure 2.2). Care was taken to 
prevent bubbles from forming between the gel and membrane, which may 
hinder complete transfer. The transfer was carried out for at least 3 hours, or 







Figure 2.2: Schematic diagram of Southern Blot transfer setup. 
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2.2.10.3. DNA hybridization and detection 
Prior to hybridization, the membrane was transferred into a roller bottle and 
equilibrated in DIG Easy Hyb (10ml/100cm2, Roche) for 30 minutes at 65°C 
in a hybridization oven. The denatured probe (described in Section 2.5.1) was 
then added in the pre-heated DIG Easy Hyb solution (3.5ml/100cm2) and 
incubated overnight at 65C with gentle agitation. Post hybridization washes 
were then performed using the DIG Wash and Block Buffer Set (Roche). The 
membrane was first subjected to a series of stringency washes: (1) 2 x SSC 
(See appendix for composition) + 0.1% SDS for 5 minutes at 65°C, (2) 0.1 x 
SSC + 0.1% SDS for 15 minutes at 65°C, twice per type of wash.  Following a 
brief rinse with 1 x DIG Washing Buffer, the membrane was incubated in 1 x 
Blocking solution (10 x Blocking solution in 1 x Maleic acid buffer) for 30 
minutes to reducing non-specific binding. The Blocking buffer was removed 
and the membrane was incubated in 10ml of α-DIG-alkaline phosphatase 
(AP)-conjugated antibody solution (5000-fold dilution in 1 x Blocking 
solution, Roche) for 30 minutes at room temperature under gentle agitation. 
Finally, the membrane was washed twice with 1 x Washing buffer for 30 
minutes each, prior to detection. For immunological detection, 10 ml of 
NBT/BCIP solution (50-fold dilution in detection buffer containing 0.1 M 
Tris-HCl, 0.1 M NaCl, pH 9.5) were gently poured onto the membrane. BCIP 
serves as a substrate for the α-DIG-AP, which oxides to a dark-blue indigo dye 
upon dephosphorylation, while NBT is an oxidant which enhances the 
sensitivity of the detection by intensifying the colour. 
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2.2.11. RNA isolation and Real-time PCR 
Mycobacterial cultures were treated with two volumes of RNAprotect 
Bacterial Reagent (Qiagen) for 15 minutes, to stabilize RNA and prevent post-
harvest induced transcriptional changes. The treated bacterial cells were 
harvested by centrifugation, and incubated with 20 mg/ml lysozyme (Sigma) 
for 20 minutes at room temperature to weaken the peptidoglycan layer of the 
mycobacterial cell wall. Total RNA was then isolated from the bacterial cells 
using the RNeasy® Mini Kit (Qiagen), according to the manufacturer’s 
instructions. Contaminating genomic DNA from the eluted total RNA was 
removed using the TURBO™ DNA-free kit according to the manufacturer’s 
protocol. The RNA concentrations and purity were measured using Nanodrop 
1000 SpectrophotometerTM (Thermo Scientific). cDNA was synthesized from 
the total RNA using the iScript™ cDNA synthesis kit.  







The reaction mix was incubated in following conditions: 
Temperature Time 
25ºC 5 minutes 
42ºC 30 minutes 





Component Volume (l) 
5x iScript reaction mix 4 
iScript Reverse transcriptase 1 
Nulcease free water 5 
RNA template (500 to 1000g total RNA) 10 
Total 20 
Chapter 2: Materials and methods 
70 
 
Real time qualitative PCR was performed using the 7500 Fast Real-Time PCR 
System (Applied Biosystems). The reaction mix was prepared with the cDNA 
synthesized earlier, primers of the target genes (Table) and iTaq™ SYBR® 
Green Supermix with ROX, as shown below:  
Component Volume (l) 
2X iTaq™ SYBR® Green Supermix with ROX 25 
cDNA 2 
Upstream and downstream primers (10M) 1 (0.5 each) 
Nuclease free water 22 
Total 50 
 
The cycling conditions were as followed: 
Stage Temperature Time Cycle 
Holding 95ºC 3 minutes 1 
Cycling 
95ºC 15 seconds 
40 
Annealing temperature of primers 45 seconds 
Melt curve 
95ºC 15 seconds 
1 
59ºC 1 minute 
95ºC 30 seconds 
60ºC 15 seconds 
 
The relative expression level of each gene was calculated by using the sigA 
transcript to normalize for RNA amounts. The relative expression of the gene 
(RQ) was determined by comparing to mid-log phase WT culture. For SF 
related experiments, the relative quantification (RQ) of the gene was 
determined by comparing to mid-log phase WT culture incubated with SF 
buffer.  
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2.2.12. Deep sequencing 
2.2.12.1. RNA seq library preparation 
Following total RNA isolation (Section 2.2.11), mRNA was purified by 
depleting bacteria ribosomal RNA (rRNA) from the total RNA, with 
Ambion’s MICROBExpress Kit (AM1905) as per the manufacturer’s 
instructions. The cDNA libraries were generated from the bacterial rRNA-
depleted sample as follows: fragmentation, 1st and 2nd strand cDNA synthesis, 
end-repair, A-tailing and ligation of adapters with multiplex indexes, using the 
TruSeq RNA sample Preparation kit v2 as per the manufacturer’s instructions.  
Following which, samples underwent 15 PCR cycles enrichment followed by 
Agencourt AMPure XP magnetic bead (Beckman Coulter, Brea, CA, USA) 
clean up according to manufacturer’s instructions. A quantitative PCR (qPCR) 
step was preformed to ensure all material subjected to sequencing contained 
the adaptors and indexes.  
2.2.12.2. Multiplexed Sequencing 
Next generation sequencing (NGS) was done using Illumina Hiseq 2000 flow 
cell, 2 x 76 base pair-end runs. PhiX was used as control. Sequencing and 
demultiplexing was carried out by the Genome Technology Biology team in 
Genome Institute of Singapore.  
2.2.12.3. Analysis of RNA-Seq data 
Unix Korn Shell was used to access the server and perform the analysis. CLC 
Genomics platform was used to generate the reads per kilo base per million 
(RPKM) values.  The quality of reads were assessed based the base per quality 
quantile and coverage plots. The digital gene expression read counts between 
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different groups were analysed using the edgeR R package, using the exact 
Test function to test for the association of the differences in digital gene 
expression read counts between the groups and the P-values were calculated 
for each gene. For each gene, their calculated P-values in –log10 scale on the 
y-axis and the gene positions on the x-axis were plotted as the Manhattan plot. 
The gene positions for each gene were derived by adding up the gene starting 
position and half the size of the gene.  The quantile-quantile (QQ)-plots for 
each analysis were plotted to examine the distribution of the observed 
empirical P-values calculated by the test model versus the distribution of the 
P-values under the expected null model. Bonferroni correction was performed 
to reduce the chances of obtaining false-positive results. A modified critical P 
value was calculated by dividing the critical P value (α = 0.05) by the total 
number of genes studied in the genome (Bland & Altman, 1995), and applied 
as a cut-off to further select for significantly modified genes. Further 
functional annotation clustering analysis was performed using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) version 6.7 
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2.3. Cell Biology 
2.3.1. Preparation of primary macrophages (BMMФs)  
Primary macrophages were prepared from bone marrow cells extracted from 
mice. Marrow cells were flushed from femurs of 6 – 8 week old Balb/C mice, 
seeded onto petri dishes (4 femurs per dish, Greiner) and differentiated into 
macrophages over 6 days in BMMФ complete medium supplemented with 10 
ng/ml recombinant mouse macrophage colony stimulating factor (rM-CSF, 
R&D Systems). . Differentiated macrophages were recovered by dislodging 
them in cold 1 x phosphate-buffered saline (PBS) containing 1mM EDTA 
pH7.4 and washed once in 1 x PBS. To prepare activated macrophages, the 
complete medium was supplemented with 10% horse serum (Gibco) and 
macrophages were activated with 100 U/ml recombinant mouse IFN-
(Chemicon) and 10 ng/ml lipopolysaccharide (LPS) for 48 hours. Primary 
macrophages consistently represented 70-80 % of the total cell population 
harvested, as determined by flow cytometry using a pan macrophage marker, 
anti- F4/80 antibody (eBioscience).   
2.3.2. Secondary cell lines 
Lung adenocarcinoma epithelial A549 cells were maintained in A549 
complete media (see appendix) and incubated at 37ºC and 5% of atmospheric 
CO2 
2.3.3. Mammalian cell infection assay 
Monolayers (5 x 104 cells/well) in 24-well tissue culture plates (Nunc) were 
incubated with mycobacteria at a multiplicity of infection (MOI) of 2 for 45 
minutes in their respective incomplete culture media (culture media without 
penicillin/streptomycin and fetal bovine serum (FBS)). The monolayers were 
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washed twice with 1 x PBS and respective complete culture media without 
penicillin/streptomycin was added to each well. At the indicated time points, 
the monolayers were washed with 1 x PBS and lysed with 0.1% Triton X-100 
(Sigma-Aldrich) to release the intracellular bacteria. The cell lysates were 
serially diluted in 7H9 medium and plated on 7H11 agar. The number of 
colony forming units (CFU) was enumerated after incubation at 37 °C for 16 
days.  
 




2.4.1. Measurement of urease activity 
Mycobacterial urease activity was determined using BD BBLTM TaxoTM 
Differentiation Disc Urea Kit (Becton Dickinson) as previously described 
(Jassal et al., 2010). Mycobacterial cultures were grown to mid-log phase 
(OD600 0.6-0.8) and adjusted to 1x109 CFU/ml in Middlebrook 7H9 medium. 
The bacterial culture was incubated with the urea disk at 37 °C. Colorimetric 
changes were monitored after one day and up to 10 days post-urea disc 
introduction.  A change of color of the suspension to red was scored as urease-
positive. 
Chapter 2: Materials and methods 
76 
 
2.4.2. Measurement of ammonia 
The ammonia (NH3) content in the spent culture media was measured using 
the Ammonia Assay kit (Sigma-Aldrich) according to the manufacturer’s 
protocol with slight modifications. Mycobacterial cultures were grown in 7H9 
to mid-log phase (OD600 0.6-0.8) and were first filtered using a 0.22 micron 
filter (Millipore) to obtain a cell-free spent culture media. 20 l of samples 
(undiluted and 10-fold dilution in minimal medium) were added to 200 l 
Ammonia Assay Reagent in a flat bottom 96-well tissue culture plate and the 
mixture was incubated for 30 minutes before initial absorbance reading at 340 
nm (OD340). L-glutamate dehydrogenase [10 l of a 10-fold dilution in 
UltraPure™ DNase/RNase-Free Distilled Water (Invitrogen)] was added to 
each well and the reaction was incubated for 5 minutes before reading the 
absorbance at 340nm. NH3 concentrations were calculated based on the 
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2.4.3. Measurement of phagosomal pH  
Assessment of phagosomal pH of Mtb phagosomes was performed according 
to previous literature (Wong et al., 2011). Mtb bacteria were labeled with 
40µM pHrodo succinimidyl ester (SS; Invitrogen), which emits red 
fluorescence in acidic environment, in PBS supplemented with 0.05% 
Tween80  pH 9 at 37ºC for 1 hour. The bacteria were washed thrice with 7H9 
to remove the excess dye. Resting or activated mouse BMMs (5x105/well) 
were infected with the labeled mycobacteria at an MOI of 10 for 2 hours. As a 
control, Concanamycin C (200 nM), a potent inhibitor of the V-ATPase proton 
transport, was added to the infected macrophages as indicated. Non-
internalized bacteria were then washed away, and the macrophages were 
further incubated for 2 hours. The cells were trypsinized and fixed with 4% 
paraformaldehyde. The fixed cells were then analyzed by FACS on BD LSR 
Fortessa and FlowJo 7.6.5 software.   
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2.4.4. Preparation of iron-dextran (Fe-Dex) 
The Fe-Dex was prepared according to previous literature (Alonso et al., 
2007). 1.2 M FeCl2 (10ml) was mixed with an equal volume of 1.8 M FeCl3 
and agitated extensively while 10 ml of 30% NH3 was added drop-wise into 
the solution. 5% NH3 (100 ml) was then added to the solution, which was 
placed on a magnet until the precipitate had formed at the bottom. The 
supernatant was decanted, and the precipitate was washed with three 
sequential changes of H2O. The sediment was suspended in 80 ml of 0.3 M 
HCl and stirred for 30 minutes. Dextran (40 kDa, 4g) was added and the 
mixture was stirred for a further 30 minutes. The solution was dialyzed against 
H2O with 4 to 5 changes over a 2-day period, until its pH reaches 5.5.  This 
suspension was centrifuged for 20 minutes at 20,000 g to pellet aggregates and 
filter-sterilised. The sterile solution was stored at 4°C. 
2.4.5. Extraction of lysosomal soluble fraction (SF)  
The lysosomal soluble fractions (SF) were extracted from activated BMMas 
previously described (Alonso et al., 2007). T75 flasks of confluent BMMs 
were incubated for 2 hours at 37 ºC and 5% CO2 with 5 ml of 40 mg/ml Fe-
dextran (40kDa) mixed with 2x Optimem (Gibco) at 1:1 ratio. The monolayers 
were rinsed twice in 10 ml of warmed sterile PBS to remove the excess Fe-
dextran and chased for overnight in culture medium. The cells were scrapped 
in 5 ml of Homogenization Buffer (HB) (250 mM sucrose, 0.5 mM EGTA, 
0.1% gelatin, and 20 mM Tris at pH 7.0) and centrifuged at 1,500 rpm at 4°C 
for 10 minutes. The pellet was resuspended in 1 ml HB and the cells were 
lysed by passing through a tuberculin syringe. The lysate was subjected to low 
speed centrifugation at 1,000 rpm at 4ºC for 10 minutes to remove debris, 
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nuclei and un-lysed cells. The supernatant was applied onto a MiniMACS 
column (Miltenyi Biotech) placed on a magnetic stand to retain the iron-
loaded lysosomes. After two washes with HB, the column was removed from 
the magnetic stand, and the bound iron-loaded lysosomes were eluted twice 
with 500 l of HB. The lysosomes were spun down at 12,000 rpm for 30 
minutes and stored as a dry pellet at –20C until use. To prepare the lysosomal 
soluble fraction (SF), each pellet was each resuspended in 200l of 1% 
Tween20-20mM sodium acetate pH 5.5. The lysates from eight pellets (2.5 x 
108 cells) were pooled together and applied onto two MidiMACS (Miltenyi 
Biotech) columns to remove iron. The flow-through was collected and 
centrifuged at 100,000 rpm at 4ºC for 50 minutes. The supernatant 
corresponding to the SF was collected and the total protein content was 
estimated using the BCA Protein Assay kit (Thermo-Scientific Pierce). SF was 
stored at –80ºC until use.     
2.4.6. BCA Protein assay 
The total protein concentration of the SF was determined using the BCA 
Protein Assay kit (Thermo-Scientific Pierce) according to the manufacturer’s 
protocol. The SF and the BSA standards were diluted appropriately in HB (see 
section above). 25l of the sample or standard were added to 200l of BCA 
Working Reagent (50 parts of Reagent A with 1 part of Reagent B) into a flat 
bottom 96-well tissue culture plate (Nunc), and incubated at 37ºC for 30 
minutes. The plate was cooled to room temperature and the absorbance of the 
samples and standards was measured at or near 562nm on the Tecan Infinite 
200 PRO multimode reader. 
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2.5. Mycobacteria specific assays 
2.5.1. Anaerobic shift-down assay 
The anaerobic shift-down assay was performed on the Mtb strains as 
previously described (Tan et al., 2010). Mycobacterial cultures were grown in 
Dubos medium and harvested at mid-log phase (OD600 0.6-0.8). The bacterial 
cells were washed twice in 1 x PBS supplemented with 0.05% Tween-80 
(PBS-T), and re-suspended in Dubos medium at a final OD600 of 0.1.  Where 
indicated, the culture medium was supplemented with urea at a final 
concentration of 3.5 mM. The bacterial suspension was then distributed in 24-
well tissue culture plates (1 ml/well). Methylene blue (1.5g/ml) was added as 
an indicator of oxygen depletion in control wells. The plates were incubated in 
air-tight anaerobic containers (BioMerieux) with Anaerogen gas packs (Oxoid) 
to generate anaerobic atmospheric condition. Atmospheric oxygen depletion 
was indicated by the anaerobic indicator strip (BD Diagnostics). Hypoxia was 
typically achieved within 24 hours after incubation under anaerobic conditions, 
as witnessed by the complete decolorization of the oxygen sensor methylene 
blue. Survival was monitored by CFU count up to 10 days after methylene 
blue decolorization. Each experimental sample consisted of triplicate wells. 
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2.5.2. Bactericidal assays 
Mtb bactericidal assays were performed with SF and several purified anti-
microbial peptides. Synthetic anti-microbial peptides human LL-37 and -
defensin 1 (HNP-1) were obtained from the Peptide Institute (Japan), and were 
reconstituted in 0.01% acetic acid for storage in -80ºC until use. Mid-log 
phased mycobacteria grown in 7H9 (5 x 105 CFU /ml) were treated with the 
indicated concentrations of the peptides or SF for an indicated period of time. 
The number of surviving bacteria was enumerated by plating appropriate 
dilutions of the mixture on 7H11 agar and incubating at 37ºC for three weeks.  
 
2.5.3. In vitro lysosomal exposure model 
Mtb cultures were subjected to sub-lethal lysosomal conditions in the in vitro 
lysosomal exposure model. As the killing activity of each SF preparation 
varies from batch to batch, the sub-lethal lysosomal conditions, which are 
defined as  a specific SF concentration (in total protein content) for a period 
of time that results in reduced viable CFU when compared to that incubated 
for the same period of time in buffer only, were pre-determined for each SF 
batch by performing a bactericidal assay (Section 2.5.2). Following which, 
1 x 108 bacteria, grown in 7H9 medium and harvested at mid-log phase 
(OD600 0.6-0.8), were incubated with the pre-determined sub-lethal lysosomal 
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2.5.4. Drug susceptibility assays 
The minimal inhibitory concentrations (MICs) were determined using 2-fold 
serial dilutions of the drug compounds, which were first prepared at 40x stock 
concentration in their respective solvents. Mid-log phased mycobacterial 
cultures (200 µl) grown in 7H9 medium were diluted to OD600 0.02 and added 
to the 5ul of the compound in a flat bottom 96–well plate and incubated for 
five days. Optical densities of the cultures were measured on the Biorad iMark 
Microplate Absorbance Reader at 600nm. The values were plotted against the 
log concentrations of the compound and a sigmoidal dose-response curve was 
fitted to the plot. The MIC values were derived from the curve, which 
correspond to the drug concentration which inhibits 100% of visible bacterial 
growth based on OD600. 
 
2.6. Animal work 
All animal procedures were approved by the ethical committees of the 
Scientific Institute for Public Health - Veterinary and Agrochemical Research 
Centre (IPH-VAR), Institutional Animal Care and Use Committees of 
National University Singapore (IACUC-NUS), and Defense Science 
Organization (DSO) National Laboratories under the protocol numbers 
100219-01, 073-10 and 10-105, respectively. In the ureC study, B6D2/F1 
mice (Janvier, Le Genest, France) were inoculated under anesthesia with Mtb 
WT and ureC strains via the intra-tracheal route, at 104 CFU per mouse. In 
the rv1285c study, Balb/C mice (CARE, Singapore) were inoculated under 
anesthesia with Mtb WT and rv1258c strains via the intra-tracheal route, at 
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103 CFU per mouse. Four animals per group were sacrificed at the indicated 
time points. The lungs, spleen and liver were aseptically harvested and 
homogenized in PBS with either an antibiotics mixture PANTA (Biomerieux) 
or 0.01% Triton X-100 (Sigma-Aldrich). The organ homogenates were 
appropriately diluted in PBS and plated onto 7H11 agar plates containing 
0.0007% cyclohexamide solution (Sigma-Aldrich) and 20g/ml ampicillin. 
CFU were enumerated after 16 days of incubation at 37C. 
2.7. Meta-analysis 
Publications were selected for meta-analysis based on the relevance of the TB 
model used during the study. The studies selected are based on macrophage 
models of TB infection, specifically the short-term (Homolka et al., 2010; 
Schnappinger et al., 2003) and extended (Rohde et al., 2012) infection 
models. One study based on the mouse model of TB infection (Talaat et al., 
2004) was also selected for analysis. Only differentially expressed genes 
(which are considered significant based on the criteria set for statistical 
significance in each study) from the studies were considered for comparison 
with our list of SF-modulated genes.  
 
2.8. Statistics 
Statistical significance was assessed by the Student’s t-test, and two-tailed p 
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3.1. Introduction  
Ureases have been described as a virulence factor in several pathogenic 
bacteria. Specifically, the alkalizing effect of ammonia produced upon 
ureolysis has been proposed to contribute to bacterial pathogenesis. It has been 
evidently shown that the presence of urease activity does neutralize the acidic 
environment encountered by Helicobacter pylori and Yersinia enterocolitica, 
thereby promoting colonization and survival of these pathogens within the 
gastric mucosa (Burne & Chen, 2000; Mobley et al., 1995; Young et al., 1996). 
The Mtb urease has been functionally characterized (Clemens et al., 1995), but 
its actual physiological role and contribution during infection has not been 
determined. Several studies have illustrated that the mycobacterial (BCG) 
urease contributes to alkalizing the mycobacteria-containing vacuole in 
macrophages (Grode et al., 2005a; Mukai et al., 2008; Sendide et al., 2004) 
and it was therefore proposed that the mycobacterial urease activity helps 
promote a more favorable microenvironment for the bacilli intracellular 
persistence. However a urease-deficient M. bovis BCG mutant was not 
impaired in its ability to survive within THP-1 human macrophages and in 
mice (Reyrat et al., 1996). Nevertheless, these observations have never been 
confirmed with the Mtb urease.  
The ability of the mycobacterial (BCG) urease to alkalize the 
microenvironment has been exploited to develop a novel BCG-based vaccine 
candidate consisting of a urease knock-out BCG mutant expressing the L. 
monocytogenes listeriolysin (Grode et al., 2005a). In the absence of the 
mycobacterial urease activity, BCG maintained a mild acidic pH within the 
bacilli-containing vacuole, providing an ideal pH environment for 
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lysteriolosyin (hyl) to perforate the vacuole membrane. Following the lysis of 
the phagosome, mycobacterial antigens were translocated into the cytoplasm, 
and induced apoptosis of infected macrophage, which resulted in stronger 
immune responses that provided better protection upon Mtb challenge. 
Employing a similar strategy, the immunization of mice and guinea pigs with 
a urease-deficient BCG strain expressing perfringolysin O (pfo) and over-
expressing key immuno-dominant antigens resulted in enhanced immune 
responses (Sun et al., 2009a). Both the ure::hyl-(VMP1002) and pfo 
(AERAS-422)-expressing BCG vaccine candidates are currently undergoing 
phase 1 clinical trial.  
The alkalizing effect produced by M. bovis BCG urease activity was also 
demonstrated to attenuate MHC class II molecule expression in infected THP-
1 human macrophages (Sendide et al., 2004) , which consequently led to the 
inhibition of CD4+ T-cell activation (Mukai et al., 2008), suggesting that the 
mycobacterial urease may contribute to suppress host immune responses. In 
addition to their ability to raise the pH in their microenvironment, most 
ureolytic bacteria are also capable of assimilating urea as a nitrogen source in 
anabolic processes such as amino acid biosynthesis, for bacterial growth 
(Figure 3.1) (Mols & Abee, 2008; Williams et al., 1996). While carbon 
metabolism has emerged as a major determinant of Mtb pathogenicity, 
nitrogen metabolism of Mtb has received little attention. As reviewed earlier 
(see Introduction, Section 1.3.2.1 & 1.3.2.2), Mtb preferentially utilizes host 
derived carbon-based sources such as fatty acids, cholesterol and lipids for in 
vivo persistence and sustainability. Conversely, Mtb assimilates ammonium, 
and synthesizes essential amino acids, which are both critical for in vivo 
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survival.  Given that the Mtb urease activity and its gene expression were 
found to increase upon nitrogen deprivation (Clemens et al., 1995), one might 
hypothesize that urea is a potential source of nitrogen for Mtb and other 
pathogenic mycobacteria. To date, the role of the mycobacterial urease in 
nitrogen metabolism has never been reported. 
In this study, we investigated the role of the urease activity in Mtb infection 
and nitrogen metabolism. We constructed a urease-deficient Mtb strain and 
confirmed the alkalizing effect of the Mtb urease activity in macrophages, 
although it did not confer any growth advantage to the pathogen. In contrast, 
we demonstrated that the Mtb urease activity plays a role in the bacterium 
central metabolism by providing a source of nitrogen when urea is readily 










Figure 3.1: Glutamate biosynthesis in Mtb and urea hydrolysis. The 








3.2.1. Construction of an unmarked Mtb ureC mutant and its 
complemented counterpart. 
A urease-negative (ureC) mutant was constructed in the Mtb CDC1551 
background. The ureC open reading frame (ORF), which encodes one of the 
three structural subunits of the holoenzyme was deleted via double 
homologous recombination, replaced by a hygromycin resistance (hygr) 
cassette as described in Section 2.2.8.1. The deletion of ureC was further 
confirmed by Southern blot as shown in Figure 3.2B.  As ureC ORF is part of 
an operon (Figure 3.2A), the insertion of the hygr cassette had exerted a polar 
effect on the downstream genes of the operon, as evidenced by the reduced 
transcriptional activity of ureF, the ORF immediately downstream ureC 
(Figure 3.2A). Since such polar effect would have precluded complementation 
studies, the hygr gene cassette was thus removed, as described in Section 
2.2.8.4, to give the unmarked ureC mutant, where transcriptional levels of 
the downstream genes in the operon was restored to that of WT (Figure 3.2C). 
The ureC mutant was then complemented, whereby the ureABC portion of 
the urease operon expressed under its original promoter was introduced in the 
ureC unmarked mutant using the promoter-less integrative plasmid pMV306 
as described in Section 2.2.8.3(Stover et al., 1991). A colorimetric assay, as 
described in Section 2.4.1, was performed to assess the urease activity in the 
ureC mutant, WT and complemented strains. Both cultures of the WT and 
complemented (Comp) strains turned pink upon incubation with a urea disc, 
while the culture of the ureC mutant remained yellow, indicating the absence 
of urease activity in the mutant strain (Figure 3.2D). No growth defect was 
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observed for the ureC mutant when grown aerobically in a standard culture 
medium (7H9) (Figure 3.2E), indicating that the loss of the Mtb urease activity 











































Figure 3.2: Construction of the Mtb ureC mutant and its complemented 
strain.  
(A) Schematic organization of Mtb urease locus (ureABCFGD). The ureC 
mutant was obtained by introducing a hyg cassette into the ureC ORF (hyg 
ureC). Removal of the hyg cassette led to an unmarked ureC mutant. 
Restriction sites (RE) and Southern blot probe are indicated (S, SalI; probe 
represented by double-headed arrow). (B) Southern blot analysis. M, DIG-
labeled molecular ladder. (C) Transcriptional activity of ureC and ureF ORFs 
in the hygureC and ureC mutants as determined by real-time PCR analysis. 
(D) Urease activity in WT, ureC, and complemented (Comp) strains 
determined by a colorimetric biochemical assay. (E) In vitro growth kinetics in 
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3.2.2. Mtb urease contributes to the alkalization of the phagosomal pH 
but not to the persistence of bacilli in macrophages. 
Earlier studies have suggested that the mycobacterial (BCG) urease may be 
involved in the intracellular persistence of the bacilli through alkalization of 
the pH within the mycobacteria-containing vacuole in macrophage (Grode et 
al., 2005a; Mukai et al., 2008; Sendide et al., 2004). To examine this 
hypothesis in Mtb, resting or (IFN+LPS)-activated BMMФ, prepared as 
described in Section 2.3.1, were infected with WT, ureC or complemented 
mycobacteria labeled with pHrodo, a pH-sensitive fluorescent dye that 
increases its fluorescence intensity with acidity, at an MOI of 10 (Wong et al., 
2011). FACS analysis of the infected macrophages revealed a slight but 
significant shift for the ureC-infected resting BMMФ compared to that 
observed with the WT strain, indicating a more acidic phagosomal 
environment for the mutant bacteria (Figure 3.3A). This shift was not 
observed in infected activated BMMФ where the mean fluorescence 
intensities for the ureC- and WT-containing vacuoles were comparable 
(Figure 3.3B), while WT-infected activated BMMФ treated with 
concanamycin C, a potent vacuolar-type H+-ATPase inhibitor, displayed a 
clear shift towards the left (Figure 3.3C). This observation thus suggested that 
the mycobacterial urease activity in the WT strain is not sufficient to alkalize 
significantly the more acidic phagolysosomal environment within activated 
macrophages. Interestingly, lower fluorescence intensities were clearly 
measured for the complemented strain compared to the WT strain in both 
resting and activated macrophages, indicating that the complemented 
mycobacteria are residing in a less acidic micro-environment. This may reflect 
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a greater urease activity in the complemented strain than in the WT strain 
which could result from the integration of the ureABC fragment at a different 
genetic locus in the genome of the complemented strain compared to the 
original urease operon in the WT strain, thereby leading to a differential gene 
expression level. 
To correlate the alkalizing effect of the urease activity to the intracellular 
persistence of the bacilli, resting and activated BMMФ were infected with the 
ureC mutant, WT and complemented strains and their infection profiles were 
monitored over time. Similar infection profiles were observed in resting 
macrophages for all the strains (Figure 3.4). Interestingly, significantly higher 
CFU counts were obtained with the ureC mutant at day 5 post-infection in 
activated macrophages, possibly suggesting that the lack of urease activity 
confers a greater ability to persist to mycobacteria (Figure 3.4B). One could 
speculate that Mtb urease activity leads to an accumulation of toxic by-
product(s) that are detrimental to mycobacteria. Such toxicity was not seen in 
resting macrophages. 
In addition, the survival ability of the WT and ureC strains was assessed in a 
hypoxic acidic in vitro model, which is believed to partially mimic the 
translocation of Mtb into a phagolysosomal micro-environment within the 
macrophages, as described previously (Tan et al., 2010). Here, the culture 
medium was supplemented with 3.5 mM urea in order to test whether the 
alkalizing effect of the urease activity could improve mycobacterial survival. 
However, comparable bacterial counts between the WT and ureC strains 
were obtained in all the culture conditions tested, i.e. pH 6.6 or 5.5 and in the 
presence or absence of urea (Figure 3.4C).  
Chapter 3: Role of Mtb urease 
92 
 
Together, these data indicate that the alkalizing effect of the urease activity 
does not provide Mtb with a growth advantage in macrophages or in an acidic 
hypoxic in vitro environment. 
 
 
pHrodo Fluorescence intensity 
Figure 3.3: Phagosomal pH measurement of infected macrophages.  
Shown are overlaid FACS histograms of pHrodo fluorescence intensities of 
resting (A) and activated (with IFN-and LPS) (B) murine bone marrow-
derived macrophages (BMMФ) infected with pHrodo-labeled Mtb WT (solid 
line), ureC (dotted line), or Comp (dashed line) strains and activated BMM
Ф infected with pHrodo-labeled WT with (gray line) or without (black line) 


































Figure 3.4: Infection profile of Mtb ureC mutant in macrophages.  
Resting (A) and activated (with IFN-and LPS) (B) murine bone marrow-
derived macrophages (BMMФ) were infected with Mtb WT, ureC, and 
complemented (Comp) strains at a multiplicity of infection (MOI) of 2. The 
infected cells were lysed and their bacterial CFU were assessed at 2, 5, and 7 
days post infection (p.i.). (C) Viability of WT and ureC mutant under 
anaerobic conditions at neutral (6.6) or mildly acidic (5.5) pH, in the presence 
or absence of 3.5 mM urea at day 10. Results are expressed as the means ± 
standard deviations of triplicates. Results are representative of two 
independent experiments. *, P value = 0.0164. 
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3.2.3. Urea utilization by Mtb occurs exclusively via the urease-
dependent pathway. 
In addition to their ability to neutralize the acidic environment for survival and 
colonization, urease-expressing human pathogenic bacteria such as Bacillus 
cereus and Actinomyces naeslundii are able to utilize urea as a source of 
nitrogen during infection (Mols & Abee, 2008; Morou-Bermudez & Burne, 
1999).  Furthermore, the Mtb urease activity was reported to be up-regulated 
under nitrogen starved conditions (Clemens et al., 1995). We therefore 
hypothesized that the Mtb urease activity may be involved in the bacterium’s 
central metabolism, by providing a source of nitrogen through the hydrolysis 
of urea and production of ammonia (Figure 3.1). To test this hypothesis, the in 
vitro growth kinetic of the WT, ureC mutant and its complemented 
counterpart was examined in a minimal medium containing glycerol as the 
sole carbon source and urea as the sole nitrogen source. As expected, absence 
of any source of nitrogen prevented the WT, ureC and complemented strains 
to grow substantially (Figure 3.5A), whereas the presence of 3.5 mM urea 
allowed exponential multiplication of the WT and complemented strains but 
not the ureC mutant (Figure 3.5B). To correlate the utilization of urea by the 
strains with their respective growth kinetics, the amount of ammonia (NH3) 
produced in the culture medium was measured, as described in Section 2.4.2. 
Increasing levels of NH3 were detected over time in the culture medium 
inoculated with the WT and complemented strains (Figure 3.5C), whereas no 
significant production of NH3 was detected in the culture medium inoculated 
with the ureC mutant, even at day 3 post-inoculation where the bacterial 
growth of the mutant is comparable to that of the WT and complemented 
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strains (Figure 3.5B). A higher exogenous urea concentration (71.4 mM) did 
not lead to enhanced growth of the WT or complemented strains compared to 
that observed with 3.5 mM urea, suggesting a possible saturation of the urease 
activity with the excessive amount of urea (substrate). On the contrary, this 
has allowed the ureC mutant to replicate as efficiently as the WT strain 
(Figure 3.5D). Further analysis revealed that substantial levels of ammonia 
were detected in non-inoculated culture medium supplemented with 71.4 mM 
urea suggesting the occurrence of spontaneous hydrolysis of urea, thereby 
allowing the ureC mutant to grow (Table 3.1).   
Together, these data indicated that the defect in urease activity impairs 
mycobacterial growth when urea is the sole source of nitrogen, and that the 









Table 3.1: Spontaneous hydrolysis of urea.  
Levels of NH3 in fresh minimal medium without urea, or supplemented with 
3.5 or 71.4 mM urea, not inoculated with bacteria, were measured after 10 
days of incubation. Results are representative of two independent experiments. 
 
 






















Figure 3.5: Utilization of urea as nitrogen source by Mtb.  
WT, ureC, and complemented (Comp) strains were grown in minimal media 
containing 0.2% glycerol only (A) or supplemented with 3.5mM(B) or 
71.4mM(D) urea. OD600 of the cultures were monitored over a period of 10 
days. Arrows indicate time points where the amount of NH3 present in the 
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3.2.4. Ammonia is the actual nitrogen source utilized for mycobacterial 
replication. 
To confirm that the growth impairment observed with the ureC mutant is due 
to the inability to provide a source of ammonia, and thus nitrogen, we assessed 
its growth profile in the presence of ammonium sulfate (NH4SO4). The ureC 
mutant was able to grow as efficiently as the WT and complemented strains in 
the presence of 1 or 10 mM ammonium sulfate (Figure 3.6A & 3.6B). Notably, 
the growth rates obtained with the WT and complemented strains in the 
presence of 1 or 10 mM NH4SO4 were comparable to that when grown in 3.5 
or 71.4 mM urea (Figure 3.5B & 3.5D), supporting the notion that ammonia 
generated from urea hydrolysis through the urease activity is the actual source 
of nitrogen when urea is present in the culture medium. Furthermore, addition 
of L-glutamic acid, an essential amino acid that is synthesized from ammonia 
(Figure 3.6C), led to significantly greater growth rates for all the strains, 
indicating that the conversion of ammonia into L-glutamic acid is likely a 































Figure 3.6: Utilization of other nitrogen sources by Mtb.  
WT, ureC, and complemented (Comp) strains were grown in minimal media 
containing 0.2% glycerol supplemented with 1 mM (A) or 10 mM (B) 
NH4SO4 or 0.424 g/liter glutamic acid (C). OD600s of the cultures were 
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3.2.5. Role of the mycobacterial urease activity in the mouse model of TB. 
To assess the role and importance of the mycobacterial urease activity during 
in vivo TB infection, adult immune-competent mice were infected via the 
intra-tracheal route with the WT and ureC strains, and their infection profiles 
were monitored by determining the bacterial loads in their lungs, spleen and 
liver at various time points post-infection. Comparable infection profiles in 
these three organs were obtained for both strains (Figure 3.7). These data 
therefore indicate that the mycobacterial urease activity is not required for 







































Figure 3.7: Survival of Mtb ureC mutant in the mouse model of 
tuberculosis. Bacterial loads were quantified in lungs (A), spleen (B), and 
liver (C) from mice infected with WT and ureC strains, as indicated, via the 
intra-tracheal route. Results are expressed as the means ± standard deviations 
for 4 mice per time point. Results are representative of two independent 
experiments. 
 


























































In this study, we addressed the physiological role of the Mtb urease activity. A 
urease-deficient mutant was constructed in the Mtb CDC1551 WT strain by 
deleting the ureC ORF which encodes for one of the structural sub-units of the 
urease holoenzyme. The unmarked in-frame ureC deletion did not affect the 
transcriptional activity of the downstream genes in the urease operon, and 
complementation was achieved by expressing ureABC under its original 
promoter. 
Our results indicated that absence of the urease activity did not impair the 
general in vitro bacterial fitness of Mtb. Using pHrodo-labeled mycobacteria, 
we demonstrated the alkalizing effect of the Mtb urease activity in resting 
macrophages where mycobacteria reside in a neutral phagosomal vacuole, 
consistent with previous studies performed with BCG (Grode et al., 2005a; 
Mukai et al., 2008; Sendide et al., 2004), the surrogate model organism for 
Mtb. However, the Mtb urease activity failed to significantly alkalize the more 
acidic micro-environment of the phagolysosomal compartment in activated 
macrophages. This observation thus suggested that the alkalizing effect 
provided by the mycobacterial urease activity is relatively modest, compared 
to other urease-expressing pathogens. In addition, we showed that the urease 
activity and its alkalizing effect does not confer the pathogen a greater ability 
to replicate or survive within macrophages as evidenced by comparable 
infection profiles between the WT and urease-deficient mutant.  
Understanding the metabolic needs of Mtb during infection is fundamental for 
identifying potential novel drug targets (Ratledge, 1976). Over the years, in 
Chapter 3: Role of Mtb urease 
102 
 
vitro metabolism-related studies have demonstrated that Mtb is a flexible 
bacterium that is able to metabolize a wide variety of nutrient sources for 
growth (Cook et al., 2009). Here, we showed that Mtb is able to assimilate 
urea for growth and this ability is urease-dependent. When deleted for urease 
activity, Mtb is greatly impaired in its growth ability when urea is provided as 
the sole source of nitrogen. We also showed that ammonia arising from 
ureolysis is the actual nitrogen source utilized by Mtb for its in vitro growth. 
Therefore, we propose that Mtb assimilates urea via its urease activity and this 
process generates ammonia, which is one of the key precursors for the 
biosynthesis of essential amino acids such as glutamate.  
Whereas no difference in growth profile was observed for the WT and urease-
deficient mutant in macrophages ex vivo where the culture medium contains a 
variety of carbon and nitrogen sources, the mycobacterial urease activity may 
still be important for intracellular growth and replication in nutrient-limiting 
conditions. It has been reported that arginine hydrolytic enzyme arginase 1 
was considerably induced in primary mouse macrophages upon mycobacterial 
infection (El Kasmi et al., 2008). As urea is one of the products of arginase 
catalysis (Morris, 2002), one could presume that Mtb is able to utilize urea as 
a nitrogen source arising from the mammalian catabolism during infection.  
The apparent dispensability of the Mtb urease activity in the mouse model is 
further supported by the fact that up-regulation of the mycobacterial urease 
operon or nitrogen metabolism related genes has never been reported from 
microarrays of Mtb-infected activated macrophages and mouse models of 
tuberculosis, in contrast to genes involved in carbon-based metabolism 
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(Schnappinger et al., 2003; Talaat et al., 2004). It is possible that other readily 
available nitrogen sources within the host cell, such as ammonia from the 
metabolism of nitrogenous compounds, and nitrate (Tan et al., 2010) could 
bypass the need for Mtb to metabolize urea. It has indeed become very clear 
that functional redundancy and compensatory mechanisms are hallmarks of 
Mtb virulence, as illustrated by a recent study on the Mtb fumarate reductase 
activity (Watanabe et al., 2011). In that study, the authors reported the role of 
fumarate reductase and succinate dehydrogenase for energy metabolism and 
succinate secretion, but gene deletion did not lead to an attenuation phenotype 
in the Wayne model or in the mouse model. Thus, the absence of in vivo 
phenotype observed with a urease-deficient Mtb mutant is likely to reflect the 
metabolic versatility which provides Mtb the ability to adapt to any 
microenvironment encountered in its host, where carbon and nitrogen sources 
may vary qualitatively and quantitatively. 
Alternatively, the mycobacterial urease activity may be important for the 
bacilli persistence or replication at specific sites of infection within the host. 
The occurrence of extra-pulmonary TB cases does imply the ability of Mtb to 
infect any organ and tissue, thus supporting the notion that Mtb can adapt 
extensively within its host, and is likely to rely on its ability to utilize various 
sources of energy. Consequently, it is plausible that the ability to utilize urea 
as a source of nitrogen could be critical at specific sites of infection where 
other sources of nitrogen are limited. For instance, during intestinal 
tuberculosis infection, urea containing body fluids such as saliva (Golub et al., 
1971) and tissue exudates (McLean et al., 1988), which coat the mucosal 
surfaces of the gastrointestinal tract, could provide a source of energy for the 
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bacilli to maintain bacterial replication at the site of infection, hence 
promoting disease.  
In conclusion, whereas we show that the alkalizing effect of the Mtb urease 
during macrophage infection does not appear to be involved in the pathogen’s 
survival and persistence, we demonstrate a role of the ureolytic activity in 
nitrogen metabolism which could be critical for the pathogen’s survival in 
conditions where urea represents the sole source of nitrogen. While it remains 
a challenge to dissect the actual metabolic needs of Mtb during in vivo 
infection, our findings hereby further support the metabolic versatility of this 
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4.1. Introduction  
Understanding the nature of the host-pathogen interactions at different stages 
of tuberculosis is central to new strategies for developing chemotherapies and 
vaccines. Using the microarray approach, researchers have profiled 
transcriptomes of Mtb based on an assortment of models of TB latency, 
featuring different stresses likely encountered by intracellular Mtb, such as 
acid (Fisher et al., 2002b), nitric oxide (Ohno et al., 2003), hydrogen peroxide 
(Schnappinger et al., 2003), gradual hypoxia (Muttucumaru et al., 2004), 
nutrient starvation (Betts et al., 2002) and more recently, drug-tolerant 
persister cells, which represents the residual and non-replicating population of 
infecting Mtb after drug sterilization (Keren et al., 2011). Acknowledging the 
macrophage as the primary host cell for Mtb, the Mtb transcriptome was also 
profiled when infecting primary mouse macrophages and human macrophages, 
to specifically reflect the changes within Mtb which possibly help cope with 
the pressures encountered inside the host cells. Some of the key studies 
include the short term (4 to 48 hours) (Homolka et al., 2010; Schnappinger et 
al., 2003) and extended (14 days) (Rohde et al., 2012) infection of primary 
mouse macrophages, and short term infection of human macrophages derived 
from human peripheral blood mononuclear cells (PBMCs) (Cappelli et al., 
2006) and secondary monocytic cell line (THP-1) (Fontan et al., 2008). A 
microarray analysis was also performed on Mtb in immuno-competent (Balb/c) 
mice and compared to severe combined immune-deficient (SCID) mice to 
identify mycobacterial genes influenced by the host immune responses (Talaat 
et al., 2004). While these studies have let us gain valuable insights into the 
adaptive strategies that have evolved within Mtb during an infection, such 
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information did not translate into the discovery of a new TB drug targets. One 
possible reason could be the inaccuracy of these current TB models in 
reflecting the physiological micro-environment(s) encountered by Mtb during 
infection. Due to the complexity of the disease, the exact location of bacilli 
causing latent TB remains to be defined. Furthermore, the evolution of 
intracellular Mtb could be a response to the synergistic effect of various 
parameters of the microenvironment and host, which are not represented in the 
existing macrophage infection models, where most of the profiling studies 
were performed. Also, the mouse model might not be a relevant model for 
latency as discussed in Section 1.2.1.4.  
As reviewed earlier, studies have strongly supported the notion that Mtb 
possesses the unique property to survive in the phagolysosomal compartment 
of macrophages (Section 1.3.1.2). We hence propose that the fusion of the 
mycobacteria-containing vacuole with the phagolysosomal compartment upon 
macrophage activation triggers the induction of a specific set of genes or 
program that allows Mtb to persist inside its host. Instead of a dead end for 
mycobacteria, the phagolysosome may thus represent a reservoir for non-
replicative bacilli. In an earlier study, Alonso et al have successfully isolated 
the soluble fraction (SF) of lysosomes from activated macrophages using a 
magnetic separation method, and showed that it displays mycobactericidal 
activity (Alonso et al., 2007). Leveraging on the mycobactericidal property of 
SF, we describe a novel in vitro lysosomal exposure model to identify new 
mechanisms in Mtb that are specifically triggered upon contact with the 
phagolysosomal content, thereby allowing Mtb to adapt to the intra-
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phagolysosomal environment. We subjected Mtb to sub-lethal lysosomal 
conditions, where in vitro cultures of bacilli were co-incubated for a specific 
period of time, with an indicated concentration of a lysosomal soluble fraction 
(SF) prepared from activated BMMФs. Instead of microarray, we employed 
next generation sequencing, a more sensitive and specific technology, to 
profile the transcriptome of Mtb during in vitro lysosomal exposure. The 
RNA-Seq data generated were further analyzed to reveal the corresponding 
transcriptional responses. To validate the relevance of this novel model, we 
selected one of the highly induced and functionally relevant genes, rv1258c, 
which encodes for a Tap efflux pump, to further investigate its role in 
intracellular survival of Mtb.  
 




4.2.1. Preparation and determination of killing efficacy of SF. 
SF used in this study was prepared as described in Sections 2.4.5, 2.4.6 & 
2.4.7.  As the concentration of the SF varies from batch to batch due to the 
volume of buffer used to solublise the lysosomes, a bactericidal assay was 
systematically performed on each SF preparation to determine its killing 
efficacy, as described in Section 2.4.8. The CFU enumerated for each SF 
treatment is expressed as a percentage of CFU enumerated for the same time 
incubation without SF treatment. Figure 4.1 shows a representative 
bactericidal data set obtained with one particular batch of SF.  As expected, 
SF-mediated killing of mycobacteria occurred in a dose- and time-dependent 
manner. After 24 hours of incubation, 65% of the bacteria remained viable 
after treatment with 25µg/ml of SF. A very low percentage of viable bacteria 
(<20%) was recovered after 24 hours of incubation with 37µg/ml of SF or 48 
hours of incubation with either 25 or 37 µg/ml of SF. Based on this assay, we 
could thus determine the sub-lethal lysosomal conditions for each batch of SF, 
which is defined as the time of incubation with an indicated SF concentration 























Figure 4.1: Bactericidal activity of SF. Bacterial cells from mid-log phase 
culture of Mtb wild type (WT) were incubated with indicated SF 
concentrations for 24 and 48 hrs. The bacterial CFUs were then enumerated, 
and expressed as a percentage of viable CFU in SF buffer incubated for the 
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4.2.2. RNA-Seq data analysis revealed a highly modulated yet unique 
transcriptome of Mtb in the in vitro lysosomal exposure model 
To profile the transcriptional changes of Mtb based on the in vitro lysosomal 
exposure, we perform next generation sequencing on RNA extracted from 
mid-log phased cultures of Mtb CDC1551 WT strain exposed to sub-lethal 
lysosomal conditions. Based on the batch of SF we have used, the sub-lethal 
lysosomal conditions were determined to be 48 hours of incubation with 
37g/ml SF, which resulted in 46% of viable CFU (Appendix 5, Figure A5.1). 
Total bacterial RNA was extracted and processed to separate rRNA from the 
mRNA, which was subsequently used to generate cDNA libraries preparations, 
as described in Section 2.2.12. Illumina-based sequencing was then performed 
on the libraries. Base per quality quantile plots indicated that the quality of 
paired end reads (sequences) generated were excellent (Appendix 5, Figure 
A5.2). Coverage plots generated after alignment with CDC1551 WT reference 
genome displayed a Poisson distribution with high coverage of more than 340, 
indicating that the sequences generated were of high accuracy. Based on the 
less stringent critical P value of 0.05, a total of 306 mycobacterial genes were 
found to be differentially expressed upon exposure the sub-lethal lysosomal 
condition, of which 112 genes were induced, while 194 genes were repressed 
(Appendix 6). Functional annotation clustering analysis (DAVID and TB 
Database) further classified the SF-modulated genes into ten functional 
categories (Figure 4.2). Disregarding genes that are either hypothetical or of 
unknown function, we generally observed that a high proportion of the 
differentially expressed mycobacterial genes are involved in metabolism, 
intermediary metabolism and cell wall and cell processes (Figure 4.2). In 
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addition, a notable number of genes were exceptionally modulated with high 
fold changes ranging from 4 to 8 (Figure 4.2).  
 
Comparison with previous intracellular Mtb transcriptomes revealed a 
signature gene profile of Mtb from in vitro lysosomal exposure model 
To establish the relevance of our in vitro lysosomal exposure model, we 
selected a few key microarray studies on macrophages and mice infected with 
Mtb (See Section 2.7), and performed a meta-analysis to compare the these 
transcriptional profiles of intracellular Mtb with our list of SF-modulated 
genes. The meta-analysis revealed that only eight of the SF-modulated 
mycobacterial genes are commonly modulated in the all three models (Figure 
4.3). While four genes were found to be differently expressed during mouse 
infection and in vitro lysosomal exposure, a considerable number of 72 SF-
modulated genes were found to be differentially expressed in the macrophages. 
More importantly, the differential expression of the remaining 222 genes was 
exclusively observed under in vitro lysosomal exposure. Based on the above 
observations, we can conclude that the in vitro lysosomal model does mirror 
the prevalent conditions within the macrophage to a certain extent. On the 
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A major reprogramming of Mtb metabolism during in vitro lysosomal 
exposure 
The modulation of Mtb metabolic genes, specifically in carbon metabolism, 
has been relatively established for intracellular Mtb based on several models 
of TB infection. During in vitro lysosomal exposure, we observed an up-
regulation of prpC (gltA-1) and prpD (rv1130) (Appendix 6, Table A6.1), 
which express key enzymes of the methylcitrate cycle in Mtb for assimilating 
propionyl-CoA (Munoz-Elias et al., 2006), a product from the breakdown of 
fatty acids by Mtb for intracellular persistence (discussed in Section 1.3.2.1). 
It is also consistently reported that both genes are simultaneously induced with 
isocitrate lyase (icl), a key enzyme in glyoxylate cycle necessary for in vivo 
fatty acid metabolism in Mtb (Munoz-Elias et al., 2006), during macrophage 
(Homolka et al., 2010; Rohde et al., 2012; Schnappinger et al., 2003) and 
mouse (Talaat et al., 2004) infections. However, the expression of icl was not 
found to be modulated in our model, suggesting that its modulation is 
attributed to other factors present in the macrophage except the 
phagolysosomal contents, or a holistic environment represented by the 
macrophage or mouse lung.  
Genes involved in branched amino acid biosynthesis, ilvC, ilvH and ilvB, were 
also highly induced by at least five fold during in vitro lysosomal exposure 
(Appendix 6, Table A6.1). While ilvC and ilvB were found to be consistently 
up-regulated in only one short term macrophage infection study (Homolka et 
al., 2010), their fold changes were significantly lower than our observations, 
indicating an enrichment of these genes with our in vitro lysosomal exposure 
model. The lack of ilvB1 has been shown to attenuate Mtb virulence during 
Chapter 4: Identifying novel survival mechanisms of intracellular Mtb 
115 
 
infection in mice (Awasthy et al., 2009a). Taken together, the metabolism of 
branched amino acids (valine, leucine and isoleucine) could possibly be a 
phagolysosomal-induced metabolic mechanism important for intracellular 
survival of Mtb.  
A cluster of repressed metabolic genes (tgs1, rv3087, rv3740c and rv3371) 
was annotated for a putative triacylglycerol (TAG) synthase, a key enzyme in 
TAG biosynthesis within Mtb (Appendix 6, Table A6.2). Of which, only tgs1 
was showed to be responsible for accumulating Mtb TAGs in intracellular Mtb 
by incorporating fatty acids released from host TAG into Mtb TAG (Lee et al., 
2013). Moreover, together with other dormancy-related Mtb genes (hspX and 
pfkB), tgs1 was up-regulated in the intracellular Mtb that are associated with 
hypoxic lipid loaded macrophages (Lee et al., 2013) and short term 
macrophage infections (Appendix 6, Table A6.2). This is in contrast with our 
findings, where all three genes were down-regulated between -5 to -8 fold 
(Appendix 6, Table A6.2). While it remains intriguing that the expressions of 
these genes are contradicting among the transcriptome studies, nevertheless, 
we can conclude that the expression of tgs1, hspX and pfkA is commonly 
regulated.  
 
Virulence, detoxification and adaptation related genes   
Exposure to sub-lethal lysosomal conditions has led to the strong induction of 
several general stress response proteins in Mtb. These genes include hsp, 
groEL-groEL operon (groEL1 and groEL2) and members of the HspR regulon 
(grpEL, dnaK, hspR and dnaJ1), which were also found to be induced in the 
three key macrophage infection studies, but not during mouse infection 
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(Appendix 6, Table A6.1). Such over-lap therefore indicates that the stress 
experienced by Mtb during macrophage infection is exerted mainly from the 
phagolysosomal environment.  
Mce 1A, 1B, 1C, 1D, 1E and 1F form another cluster of genes that were 
consistently modulated in both macrophage and in vitro lysosomal exposure 
models (Appendix 6, Table A6.2). Belonging to the mce1 operon, these genes 
encode for mammalian cell entry (mce) proteins, with only Mce1A having 
implicated for modulating host inflammatory responses to facilitate granuloma 
formation for bacterial persistence (Shimono et al., 2003), and facilitating host 
cell invasion (Chitale et al., 2001), while an Mtb mce1E transposon mutant 
was attenuated for survival in non human primate aerosol model (Dutta et al., 
2010). Although both genes have been shown to be critical for Mtb virulence, 
its repressed expression, together with the other mce-related genes during 
short term macrophage infections (Appendix 6, Table A6.2) is an intriguing 
finding, and remains to be explored.  
Repression was also observed for MT1524, MT1525, MT1617 and MT2087, a 
group genes exclusively encoded in the Mtb CDC1551 strain and annotated 
for a putative invasion associated protein (Appendix 6, Table A6.2).  Genes 
associated with invasion are probably only required at the point of entry of the 
host cell. Hence, such observation likely indicates the down-play of redundant 
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Induced regulatory proteins are associated with intrinsic drug recalcitrance 
of Mtb 
The in vitro exposure to sub-lethal lysosomal conditions also led to the 
induction of Mtb regulatory proteins, furA and whiB7 (Appendix 6, Table 
A6.1). More interestingly, these proteins have been associated with intrinsic 
antibiotic resistance in Mtb in earlier studies. FurA is a repressor of katG 
expression in Mtb (Zahrt et al., 2001), which encodes for the sole catalase-
peroxidase of Mtb that is responsible for activating the pro-drug of isoniazid, 
rendering the bacilli sensitive to this compound. As an earlier study has shown 
that intracellular Mtb develops macrophage-induced tolerance towards INH 
(Adams et al., 2011), it is hence possible that INH tolerance exhibited by 
intra-macrophage Mtb might be conferred through the phagolysosomal-
induced expression of furA. Paradoxically, katG was induced in our study with 
a relatively low fold change of 2.77 (Appendix 6, Table A6.1). Macrophages 
produce hydrogen peroxide upon activation, which accumulates within 
phagolysosomes (Ehrt & Schnappinger, 2009). The presence of minute 
amounts of such oxidants in the lysosomal SF might have induced katG 
expression, as previously described (Master et al., 2001; Sherman et al., 1996). 
Nonetheless, it is also possible that furA is a regulator of other genes involved 
in virulence, given the partial restoration of virulence in mouse lungs when 
furA was introduced into a (furA-katG) mutant (Pym et al., 2001).  
The stress response induced transcriptional regulator, whiB7, was found to be 
up-regulated by 6.64 fold in our in vitro lysosomal exposure model. whiB7 
was described to be up-regulated under numerous stress conditions such as 
heat shock, iron starvation, a  variety of antibiotics, during stationary growth 
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phase, (Geiman et al., 2006), in the presence of exogenous fatty acids (Morris 
et al., 2005), nitric oxide, cAMP, and during infection of J774 macrophages 
and mouse lungs (Larsson et al., 2012). It also regulates a regulon of eight 
genes, whose transcription profiles appeared to be influenced by antibiotic 
exposure (Morris et al., 2005). Coincidentally, we found two of these eight 
genes, eis and rv1258c, highly expressed in our in vitro lysosomal exposure 
model, with 5.79 and 8 fold changes respectively (Appendix 6, Table A6.1). 
Of which, rv1258c has been implicated for conferring intrinsic rifampicin 
tolerance in Mtb in an intra-macrophage environment. Based on these 
observations, we conclude that the transcriptional activity of whiB7 is 
phagolysosomal inducible, and mediates the expression of rv1258c, which in 
turn confers rifampicin tolerance to intracellular Mtb.  
 
PE/PPE and ESAT-6 like related genes 
We also observed a down-regulation of a large number of PE/PPE related 
proteins in our in vitro lysosomal model. Of which, greater fold change 
ranging from -3 to -8.5 were observed for pe13, pe18, pe22 and pe31 
(Appendix 6, Table A6.2). In addition, ESAT-6 like proteins such as EsxB, 
EsxK, EsxG and EsxL were notably down-regulated with a fold change of -2.4 
to -4.76. Both ESAT-6 systems and PE/PPE families of proteins are 
considered a major source of Mtb immunogenic variation (Brodin et al., 2004; 
Mukhopadhyay & Balaji, 2011). The secretion of PE/PPE proteins and ESAT-
6 like proteins is dependent on the ESX secretion systems (Sampson, 2011), 
which have been implicated in the virulence of different pathogenic 
mycobacteria (Abdallah et al., 2006; Abdallah et al., 2009; Fortune et al., 
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2005; Teutschbein et al., 2009). Expression studies reveal that PE/PPE 
proteins are differentially expressed under different conditions. In the intra-
macrophage context, one could thus speculate that the down-regulation of 
these antigenic proteins could be a tactic to avert the host immune responses.  
 
Enrichment of mycobacterial transporters during in vitro lysosomal 
exposure 
Several mycobacterial membrane associated proteins (rv1258c, mgtC, ugpA, 
pitB, rv3000, rv1986, rv1877 and rv2459), whose role of their transport 
functions relative to the intra-macrophage and in vivo survival have not been 
highlighted in earlier studies, were found to be distinctly induced in our in 
vitro lysosomal exposure model with fold changes ranging from 2.24 to 7.9 
(Appendix 6, Table A6.1). The Mtb transposon mutant of rv2459, which 
encodes for a probable conserved integral membrane transport protein, was 
found to be attenuated for its survival in the lungs of non-human primates 
(Dutta et al., 2010).  Rv1258c, rv1986 and ugpA were also reported by 
Schnappinger et al to be mildly induced during macrophage infection (1.5 to 
2.8 fold). Particularly, rv1258c, which encodes for a putative Tap-like 
membrane efflux pump, exhibits the highest induced expression of 7.99 fold in 
our model. Interestingly, increased transcriptional activity was also observed 
in MDR clinical isolates of Mtb when exposed to sub-inhibitory 
concentrations of rifampicin, ofloxacin or isoniazid (Gupta et al., 2006; 
Siddiqi et al., 2004; Xin Jiang et al., 2008). Moreover, the over-expression of 
rv1258c in mycobacterial strains does confer intrinsic resistance to 
tetracycline, streptomycin, kanamycin, rifampicin and spectinomycin (Lee et 
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al., 2014). Mtb transposon mutants of rv1258c also showed reduced viability 
after 96 hours post macrophage infection (Adams et al., 2011). Taken together, 
it is therefore plausible that mycobacterial transporters confer an intrinsic 
adaptive role to Mtb when exposed to sub-lethal lysosomal conditions, and 
thus contributing to its intracellular survival.



















Figure 4.2: Functional categories of differentially expressed genes in Mtb 

























































































































Figure 4.3: Meta-analysis of differentially expressed genes from models of 
TB infection from previous studies and the in vitro lysosomal exposure 
model. * Gene is included if it is modulated in at least one of the three 
macrophage models (Appendix 6) 
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4.2.3. Validation of RNA-Seq data: investigating the role of rv1258c in 
the intracellular survival of Mtb 
To determine if the in vitro lysosomal exposure model is an appropriate 
approach to identify novel survival mechanisms of intracellular Mtb, we 
decided to select one of the highly induced and functionally relevant genes for 
further characterization. Our findings had revealed an enrichment of 
mycobacterial transporters, which led us to postulate that their pump and/or 
transport functions might contribute to Mtb intracellular survival and/or 
persistence via the extrusion of antimicrobial compounds out from the intra-
bacterial milieu. To test this hypothesis, we selected rv1258c to further 
characterize its role in intracellular Mtb. To validate the increased expression 
of rv1258c observed in RNA-Seq data, real time PCR analysis was performed, 
using rv1258c specific primers, on total RNA extracted from Mtb CDC1551 
WT bacteria subjected to the sub-lethal lysosomal conditions, which is 24 
hours of incubation with 25g/ml of another batch of SF preparation as 
described in Section 2.2.11. Rv1258c was significantly up-regulated by 6.1 
fold after exposure to SF (Figure 4.4), confirming the observation from the 
























Figure 4.4: Real-time PCR analysis of rv1258c expression in SF-exposed 
Mtb WT.  
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4.2.4. Construction and characterization of Mtb rv1258c mutant and its 
complemented strain, Ox-rv1258c. 
To further characterize the role of rv1258c in the intracellular survival of Mtb, 
we constructed a mutant deleted for rv1258c in Mtb CDC1551 background, 
via homologous recombination as described in Section 2.2.8.1. Deletion of 
rv1258c was confirmed by Southern blot (Figure 4.5B). As rv1258c is the first 
ORF of an operon upstream of rv1257c (Figure 4.5A), which encodes for a 
putative oxido-reductase, we examined whether insertion of the hygr gene 
cassette in place of rv1258c exerts any polar effect on rv1257c. Real time PCR 
analysis showed that the transcriptional activity of rv1257c in the rv1258c 
deleted strain was comparable to that measured in the parental strain (1.16 fold) 
(Appendix 5, Figure A5.3) indicating that the presence of the hygr gene 
cassette in place of rv1258c ORF does not interfere with the transcriptional 
activity of the downstream gene rv1257c. In addition, using a promoter-less 
integrative plasmid pMV306, the complemented strain was constructed by 
introducing the rv1258c ORF under the expression of the Mtb hsp60 promoter 
into the rv1258c mutant as described in Section 2.2.8.3. Real time PCR 
analysis showed that the expression of rv1258c was 20 times higher in the 
complemented strain, Ox-rv1258c, compared to the WT counterpart (Figure 
4.5C). In vitro growth kinetic profiles showed that rv1258c and Ox-rv1258c 
strains display a slight growth advantage compared to WT strain in 7H9 
culture media (Figure 4.5D), which might be due to an artifact during the 
cloning process, where the fittest, thus fastest growing clones, were selected.  
 
 















Figure 4.5: Construction of Mtb rv1258c mutant and its complemented 
strain, Ox-rv1258c.  
(A) Schematic organization of Mtb rv1257c-1258c locus in wild type (WT). 
The mutant was obtained by introducing a hyg cassette into the rv1258c ORF, 
and complemented by re-integrating rv1258c under Mtb hsp60 promoter (Ox-
rv1258c) into its genome. Southern blot probe and restriction enzyme sites are 
indicated (E, EcoRI ; X, XmaI ; probe, double headed arrow) (B) Southern blot 
analysis. M, DIG-labeled molecular ladder (C) Transcriptional activity of 
rv1258c in WT and Ox-rv1258c as determined by real time PCR analysis. (D) 
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4.2.5. Drug resistance levels and proton motive force dependence of Mtb 
Tap efflux pump 
The Tap efflux pump has been proposed to confer intrinsic resistance to 
multiple drugs in mycobacteria, either through basal or over-expression of 
rv1258c, and could be abolished in the presence of carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), a proton motive force inhibitor. Here, we 
determined the levels of resistance to various classes of TB drugs in our 
rv1258 mutant by performing drug susceptibility assay, as described in 
Section 2.4.9. In addition, to confirm the dependence of its efflux activity on 
proton motive force, CCCP, a proton motive force (PMF) inhibitor, was added 
at 1g/ml in the assays. CCCP abolishs the efflux action by binding to the H+ 
and disrupts the proton gradient that drives the efflux pump. This inhibitor has 
been extensively used in efflux pumps studies which have explored the PMF-
dependent efflux of antibiotics and other antibacterial substances (Padilla et al., 
2010; Ramon-Garcia et al., 2009; Shafer et al., 1998). The extent of 
susceptibility to a particular compound is determined by the value of the 
minimal inhibitory concentration (MIC) of the compound, which is defined as 
the lowest concentration of the compound that inhibits visible growth of the 
bacilli after incubation for five days. The assay was performed using a range 
of concentrations of the compounds serially diluted (2-fold dilution). The 
difference in susceptibility to the compound compared to the WT control was 
considered significant when the value obtained was greater than 2-fold 
compared to WT. As shown in Table 4.2, the susceptibilities of WT and 
rv1258c mutant strains to isoniazid, rifampicin, kanamycin and ethionamide 
were similar, and were comparable to MIC values of Mtb reported in previous 
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studies. In contrast to previous findings, rv1258c mutant did not show any 
increased susceptibility, and Ox-rv1258c strain did not show greater resistance, 
to tetracycline, which might be attributable to mycobacterial strain difference. 
Nevertheless, we observed that Ox-rv1258c exhibited a more than 17 fold 
increase in MIC value for streptomycin, and that addition of CCCP brought its 
resistance to streptomycin back to the parental level. This latest observation 
thus supported that over-expression of the Tap efflux pump is responsible for 




WT rv1258c Ox– rv1258c 
Isoniazid 0.04 0.04 0.04  
Rifampicin 0.003 0.002 0.003  
Tetracycline 1.5 2.0 2.5  
Ethioamide 2.4 1.9 1.6  
Gentamicin 0.9 0.7 1.6  
Kanamycin 1.8 1.8 N.A.  
Streptomycin 0.3 0.3 3.7  
Streptomycin + CCCP* 0.5 0.4 0.8  
 
Table 4.2: Susceptibilities of Mtb WT, rv1258c and Ox-rv1258c strains to 
TB drugs. 
MICs were assayed over a range of 2-fold dilutions of the compounds. *, 
CCCP was added at 1g/ml. N.A., Not applicable as kanamycin resistance 
gene was used as selection marker in the construction of Ox-rv1258c strain. 
Data shown is a representative of two independent experiments. 
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4.2.6. rv1258c mutant is more susceptible to anti-microbial peptides. 
Studies have shown that pathogenic bacteria do utilize bacterial efflux pumps 
to pump out host derived substrates which have anti-microbial activity, to 
resist killing. Anti-microbial peptides (AMPs) represent an important defense 
mechanism and are abundantly present in the airways to prevent the 
colonization of pathogenic bacteria. We questioned whether Mtb resists AMP 
activity in the airways by pumping them out through the Tap efflux pump. We 
thus determined the susceptibility of the mutant to synthetic human anti-
microbial peptides, human neutrophil peptide-1 (HNP-1) and human 
cathelicidin LL-37. Mtb WT, rv1258c and Ox-rv1258c mutants were 
incubated with 25 g/ml of each synthetic peptide for 72 hours (Section 2.4.8), 
and viable CFU were enumerated and expressed as a percentage of viable 
CFU obtained with the diluent only (0.01% acetic acid).  
When incubated with HNP-1, the WT strain retained 95% of viable CFU 
while the viability of mutant was reduced to 63% (Figure 4.6A), indicating a 
clear microbicidal effect of HNP-1 on the mutant at 25g/ml upon 72 hours 
incubation. Viability was not lost for the Ox-rv1258c mutant. Instead, it 
seemed to display a greater resistance to HNP-1 killing compared to the WT 
strain, although the difference was not statistically significant (Figure 4.6A). 
Based on their proposed mechanisms of action (Figure 4.12), it is has been 
suggested that AMPs require a minimal concentration to exert a microbicidal 
effect on the pathogen (Shai, 2002; Wiesner & Vilcinskas, 2010). Indeed, 
greater susceptibility was observed for all strains when 50g/ml of HNP-1 and 
LL-37 were used in our study (Appendix 5, Figure A5.4). Thus, 25g/ml is 
likely below the minimal concentration for HNP-1 and LL-37 to be 
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microbicidal. WT, rv1258c and Ox-rv1258c strains also exhibited a similar 
trend of susceptibility when incubated with LL-37, although there was no 
statistical difference among the strains (Figure 4.6B). Taken together, these 
results thus support that lack of the Tap efflux pump does increase the 
susceptibility of Mtb to AMPs, while over-expression of the pump appears to 


















Figure 4.6: Bacterial susceptibility to antimicrobial peptides.  
Bacterial cells from mid-log phase cultures of Mtb wild type (WT), rv1258c 
and Ox-rv1258c (complemented) strains were incubated with (A) HNP-1 and 
(B) LL-37 at 25g/ml for 72hrs. The bacterial CFUs were then enumerated, 
and expressed as a percentage of viable CFU with diluent only (0.1% acetic 
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4.2.7. Presence of Tap efflux pump is important for Mtb to resist in vitro 
lysosomal killing, but independent of its efflux activity. 
Lysosomes contain a rich array of hydrolytic enzymes and AMPs which has 
been described to facilitate the killing of pathogens upon fusion with 
pathogen-containing phagosomes. Killing of mycobacteria could also be 
achieved by ubiquitin-derived peptides that are present in lysosomes from 
activated macrophages (Alonso et al., 2007). Since rv1258c was found up-
regulated upon exposure to sub-lethal SF, we reasoned that it may play a role 
in Mtb survival in this hostile environment. To test this hypothesis, the relative 
susceptibility of rv1258c mutant to SF was determined by performing a 
bactericidal assay as described in Section 2.4.8. Killing was observed for the 
Mtb strains after overnight incubation with 37g/ml of SF. While WT strain 
retained 17% viability, rv1258c mutant exhibited a marked reduction of 
viable CFU to 3.3% (Figure 4.7), therefore suggesting a role for rv1258c in 
Mtb survival within the phagolysosomal compartment. Consistently, Ox-
rv1258c exhibited greater resistance to SF killing compared to WT, with 52% 
viability (Figure 4.7). To further investigate whether the efflux action of 
Rv1258c is responsible for the resistance to SF killing, Ox-rv1258c strain was 
incubated with SF in the presence of 1g/ml CCCP. Results showed that the 
viability of Ox-rv1258c was 63% in the absence of CCCP and 57% in the 
presence of CCCP (Figure 4.8). This data thus indicated that resistance to SF 
of the Ox-rv1258c strain does not involve the proton motive force, thereby 
suggesting that the role of the rv1258c product in Mtb resistance to SF is 
likely not via the efflux of anti-microbial components present in SF. 
 












Figure 4.7: Bacterial susceptibility to SF.  
Bacterial cells from mid-log phase cultures of Mtb wild type (WT), rv1258c 
and Ox-rv1258c (complemented) strains were incubated with SF at 37g/ml 
for 24hrs. The bacterial CFUs were then enumerated, and expressed as a 
percentage of viable CFU with SF buffer.  Data shown are means ± SDs of 
triplicates and is a representative of two independent experiments. *, p-value 











Figure 4.8: Susceptibility of Mtb Ox-rv1258c strain to SF in the presence 
of CCCP.  
Bacterial cells from mid-log phase culture of Mtb Ox-rv1258c were incubated 
with SF at 30g/ml for 24hrs. 1g/ml CCCP was added where indicated. The 
bacterial CFUs were then enumerated, and expressed as a percentage of viable 
CFU incubated with SF buffer.  Data shown are means ± SDs of triplicates and 
is a representative of two independent experiments. 
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4.2.8. The Tap efflux pump is required for efficient replication of Mtb in 
mouse lungs during the acute phase of TB infection.  
To establish if the Tap efflux pump plays a role during in vivo TB infection, 
we determined the infection profile of the rv1258c mutant in the mouse 
model of TB. Adult immuno-competent BALB/c mice were infected with the 
WT and rv1258c strains via the intra-tracheal route, and their infection 
profiles were monitored by determining the bacterial loads in the lungs and 
spleens at various time points post infection. Between day 10 and 35 post 
infection, the bacterial loads recovered from rv1258c-infected mice were 
notably reduced in the lungs, compared to the WT control group (Figure 4.9A). 
Bacterial multiplication then reached a plateau for both strains after day 35 
(Figure 4.9A). There was no difference in the survival profiles between both 
strains in the spleens (Figure 4.9B). These observations thus suggested that the 
Tap efflux pump may play a role during the acute phase of TB infection in 
mice, but is dispensable for its persistence. Work is currently in progress to 





































Figure 4.9: Survival of Mtb rv1258c mutant in the mouse model of 
tuberculosis. Bacterial loads were recovered from (A) lungs and (B) spleens 
of Balb/C mice infected with wild type and rv1258c via the intra-tracheal 
route. Data shown are means ± SDs for four mice per time point and is a 
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4.2.9. rv1258c mutant is notably impaired in uptake and survival in 
resting and activated BMMФs, but not in lung epithelial cells.  
To further investigate the role of the Tap efflux pump during Mtb infection, 
we examined the ability of rv1258c to infect single cell populations. As an 
intracellular pathogen, the first cells that Mtb encounters upon entry into the 
lung cavity are epithelial cells and alveolar macrophages (Agerberth & 
Guðmundsson, 2006). Monolayers of resting and activated BMMФs, and 
A549 (lung adenocarcinoma epithelial) cells were infected with Mtb WT and 
rv1258c at an MOI of 2 (Section 2.3.3) and their infectivity and infection 
profiles were determined. The infectivity of each strain corresponds to the 
number of viable CFU recovered from cell lysates after 45 minutes co-
incubation with mycobacteria. Results are expressed as a percentage of the 
inoculum for each Mtb strain. For both cell types, the WT strain displayed a 
higher infectivity (1-2%) compared to the rv1258c mutant (0.7%) (Figure 
4.10A, 4.10C & 4.11A), suggesting that the Tap efflux pump could be 
involved in the ability of Mtb to adhere to and/or invade the host cells.  
We then monitored the intracellular survival of both WT and mutant strains 
over time post-infection. However, given the difference in infectivity between 
both strains, to provide an accurate assessment of their intracellular survival, 
viable CFU enumerated at the indicated time points were expressed as a 
percentage of viable CFU enumerated after incubation for 45 minutes (day 0 
time point) and not as a percentage of the inoculum. In resting BMMФs, the 
viability of the mutant was greatly reduced (18 and 27%), compared to the WT 
(100% and 65%) in the first two days post infection, and gradually increased 
at day 5 post infection, with a slower replication rate observed for the mutant 
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(Figure 4.10B). In activated BMMФs, while minimal change in the viability of 
WT was observed, viable counts of rv1258c mutant was drastically reduced 
to 48% at day 1 post infection, and its replication rate remained relatively 
constant throughout the course of infection (Figure 4.10D). In the pulmonary 
lung epithelial A549 cells, both strains displayed reduced viability of 30-35% 
in the first two days post infection followed by bacterial multiplication by day 
5 post infection (Figure 4.11B). The comparable intracellular survival profiles 
observed for the WT and mutant strains indicated a dispensability of the Tap 
efflux pump for persistence in A549 lung epithelial cells. Taken together, 
these data indicated that the Tap efflux pump might be necessary for infection 
and resistance to killing of the tubercule bacilli in the first two days post 
infection of resting and activated BMMФs. Work is currently in progress to 



































Figure 4.10: Infection of resting and activated primary murine 
macrophages with Mtb WT and rv1258c mutant strains. 
Resting (A) and (B), and activated (C) and (D) (10ng/ml of LPS and 100U/ml 
of IFN-) murine bone marrow-derived macrophages (BMMФs) were infected 
with Mtb strains at MOI of 2. After 45 min incubation, the infected cells were 
washed with PBS to remove extracellular non-adherent bacteria (Day 0 time 
point). Infectivity (A) and (C) of each strain represented by the number of 
viable CFU recovered from BMMФ immediately after infection (and wash 
steps) and expressed as a percentage of the inoculums of respective Mtb 
strains. At indicated time points, the infected cells were lysed and viable CFU 
were recovered on 7H11 agar, and expressed as a percentage of viable CFU at 
Day 0 (B) and (D).*, P-value < 0.05. Data shown are means ± SDs of 





























































































Figure 4.11: Infection of lung epithelial A549 cells with Mtb WT and 
rv1258c mutant strains. 
A549 cells were infected with Mtb strains at MOI of 2. After 45min 
incubation, the infected cells were washed with PBS to remove extracellular 
non-adherent bacteria. (A) Infectivity of Mtb WT and rv1258c mutant 
strains. (B) Intracellular survival of Mtb WT and rv1258c mutant strains. The 
infected cells were lysed and viable CFU were recovered on 7H11 agar, and 
expressed as a percentage of viable CFU at Day 0.*, P-value < 0.05. Data 
shown are means ± SDs of quadruplicates and is a representative of two 













































Transcriptome of Mtb during in vitro lysosomal exposure 
In this study, we described a novel in vitro lysosomal exposure model to 
identify and investigate novel mechanisms of intra-phagolysosomal survival of 
Mtb. By directly exposing mycobacteria to the lysosomal soluble fraction (SF) 
from activated macrophages, we showed that the Mtb transcriptome is highly 
modulated under sub-lethal lysosomal conditions, which we proposed to have 
triggered the survival arsenal of Mtb within activated macrophages. The 
corresponding proteins are clustered into ten functional categories, which are 
similar to those reported from previous microarray studies based on 
macrophage and mouse models of TB infection. Like previous studies, the 
majority of the differentially expressed mycobacterial genes in our model are 
hypothetical and unknown proteins, indicating that our level of 
comprehending host-Mtb interactions still remains very superficial. A major 
reprogramming of the metabolism in Mtb was observed, particularly with 
some over-laps in the general stress responses and lipid metabolism. The 
phagolysosomal environment could therefore be the cue to initiate metabolic 
reprogramming in Mtb for subsequent adaptation within the phagolysosomal 
compartment of the macrophage. This observation could not emphasize further 
the urgency to completely decipher the actual metabolic status of Mtb during 
infection to propel TB drug discovery. 
The minimal overlap of 72 mycobacterial genes between our model and other 
models is a clear indication that our in vitro lysosomal exposure model 
recapitulates a very specific environmental niche that is encountered by Mtb 
during infection of macrophage or a whole mouse. Furthermore, a number of 
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stimuli encountered in the phagolysosomal compartment of an activated 
infected macrophage, such as acidity and hypoxia, are not preserved during 
the preparation of the lysosomal SF and in the experimental setup of the SF 
killing assay. For instance, although the pH of the lysosomal SF is maintained 
at 5.5, the acidity is neutralized when adding SF to the bacterial suspension 
made in 7H9 medium. Consistently, induction of previously identified acid-
resistant genes such as aprABC locus (Abramovitch et al., 2011), 
rv3671(Vandal et al., 2008a) and ptpA (Wong et al., 2011) was not observed 
in our RNA-Seq data. Our in vitro lysosomal exposure model also failed to 
capture genes such as fadD26, mbtABCDEFGH, icl, umaA, alkB and fadD33, 
which were previously described to be intra-phagosomally induced and are 
important for Mtb virulence (Schnappinger et al., 2003), thus highlighting its 
limitations as a screening model for the intra-phagolysomal survival 
mechanisms of Mtb. 
Most importantly, our model does identify new mycobacterial genes. The 
meta-analysis with gene profiles previously generated from key microarray 
studies based on macrophage and mouse models of TB infection has revealed 
a massive list of genes which are differentially expressed only in our model, 
with a majority of them involved in transcriptional or translational activities 
and in fatty acid metabolism, providing an alternative pool of gene candidates 
to be further characterized for their role in intra-phagolysosomal survival. 
Furthermore, in comparison to a more holistic environment within a 
macrophage or mouse lung, the minimalistic yet defined lysosomal 
environment led to the identification of a number of phagolysosomal-inducible 
Mtb genes, which may play a role in intra-phagolysosomal survival of Mtb. 
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Rv1258c, ugpA, eis, ivlC and ivlB, which were mildly induced during 
macrophage infections, showed a greater increase in their expression levels in 
our in vitro lysosomal exposure model. Of which, rv1258c and eis have been 
implicated for intracellular survival in mice, while rv2459, which was not 
found to be up-regulated in any macrophage or mouse models, was attenuated 
for survival in lungs of macaques (Dutta et al., 2010), thus validated our novel 
in vitro approach.  
Our findings also supported the view that drug tolerance in Mtb is induced 
upon macrophage infection, and denoted that the phagolysosomal environment 
is conducive for drug tolerance. In response to the hostile phagolysosomal 
environment, Mtb modifies its transcriptome, which incidentally provides 
intrinsic multi-antibiotic resistance, particularly through the regulatory 
proteins FurA and WhiB7. While the up-regulation of FurA might indirectly 
confer INH resistance to Mtb through katG repression, which remains to be 
further explored, WhiB7 induces the expression of eis and rv1258c, which 
were recently correlated to kanamycin and streptomycin resistance in Mtb 
respectively (Reeves et al., 2013). Furthermore, it has been shown that Mtb is 
intrinsically tolerant to rifampicin, via the efflux activity of the Tap-like 
membrane efflux pump encoded by rv1258c during macrophage infection 
(Adams et al., 2011).  
Validation of the in vitro lysosomal exposure model with rv1258c 
We validated our RNA-Seq data analysis by selecting one of the highly 
modulated genes with a potential intracellular function, rv1258c, for further 
characterization for its role during intracellular survival. Rv1258c encodes for 
a Tap-like membrane efflux pump, which belongs to the H+/ drug antiporter 
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major facilitator superfamily (MFS), and are functionally dependent on proton 
motive force (PMF). As discussed earlier, the modulation of its transcriptional 
activity in the presence of several antibiotics has been extensively studied. But 
its apparent up-regulation in a drug-free  context (SF) and reduced viability of 
its transposon mutant in macrophages (Adams et al., 2011) had led us to 
postulate that efflux activity of the membrane associated Rv1258c protein 
could also be involved in extruding anti-microbial agents present within the 
lysosomes, and thus improving the viability of intracellular Mtb. We 
constructed a mutant deleted for the rv1258c ORF in the Mtb CDC1551 
background and observed a prominent but not significant in vitro growth 
advantage compared to the parental strain, which is in contrast to the 
progressive growth defect exhibited by a BCG rv1258c mutant described 
earlier (Ramón-García et al., 2012). The progressive in vitro growth defect 
was only reported for the BCG mutant while the in vitro growth profiles of 
counterparts in other mycobacterial backgrounds have not been described. 
Moreover, our Mtb CDC1551 rv1258c was not found to be susceptible to 
tetracycline, unlike BCG rv1258c mutant (Ramón-García et al., 2012). M. 
smegmatis over-expressing rv1258c from M. fortutium and Mtb showed 
greater resistance to tetracycline (Ramón-García et al., 2006), which is 
inconsistent with our findings of the over-expressed strain, Ox-rv1258c, 
despite a high percentage of homology of rv1258c at both the DNA and 
protein levels between the mycobacterial strains. Whole genomic and 
proteomic differences between BCG and Mtb could have led to an unknown 
compensatory effect on the in vitro growth triggered in the absence of the 
efflux pump (Jungblut et al., 1999), thus restoring the growth to parental level. 
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Nonetheless, the presence of the PMF-dependent efflux activity that confers 
streptomycin resistance to Mtb was described for all the strains (Balganesh et 
al., 2012; Ramón-García et al., 2012). 
Increased susceptibility to the bactericidal activity of SF and to purified 
antimicrobial peptides (AMPs) was observed with rv1258 mutant. In 
addition, we showed that the energy-dependent efflux pump activity of 
Rv1258c protein was not responsible for the greater resistance to SF killing 
observed with the Ox-rv1258c mutant. These observations support that the 
mechanism(s) by which Rv1258 protein contributes to Mtb resistance to SF 
killing is not mediated by its efflux pump activity. Moreover, infectivity of 
rv1258 mutant was impaired during infection of resting and activated 
BMMФs, as well as lung epithelial cells, where lesser intracellular bacilli were 
recovered after 45 minutes incubation with mammalian cells. It remains to be 
investigated whether the adherence properties of the rv1258 mutant to the 
mammalian cell surface is impaired compared to the WT strain. It has been 
well-established that the impermeable cell wall protects Mtb against hostile 
environments and bactericidal agents, and also plays an active role in 
modulating the host immune response (Figure 4.11), thus representing an 
important virulence factor for Mtb (Glickman & Jacobs Jr, 2001; Karakousis 
et al., 2004). The cell wall composition is also critical for the ability of Mtb to 
adhere and infect its host cells (Yuan et al., 1998). We therefore postulate that 
the cell wall composition and/or integrity might be altered in the absence of 
the membrane-associated Rv1258c protein. It is thus conceivable that a 
different cell wall composition or impairment in its integrity in the rv1258c 
mutant compared to WT may affect its ability to confer a protective barrier to 
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AMPs, which could have better access to the inner cell membrane. This 
hypothesis may explain the greater susceptibility of the rv1258c mutant to a 
concentration of AMPs that is non-bactericidal for the parental Mtb strain. 
Upon binding to the negatively charged cell membrane, cationic amphipathic 
AMPs exert their microbicidal effect by disrupting the structure of the lipid bi-
layers of the bacterial cell membrane through the formation of ion channels, 
trans-membrane pores or extensive membrane rupture (Figure 4.12), 
eventually leading to cell lysis. (Wiesner & Vilcinskas, 2010).  Further 
supporting this rationale, we observed that survival of the rv1258c mutant 
was impaired during the first two days post infection of resting and activated 
BMMФs. Reduced bacterial loads during the acute phase of TB infection were 
also observed in mice, specifically in the lungs, infected with rv1258c 
mutant compared to the parental strain. The immediate response of the host 
innate immunity to bacterial infection comprises of AMPs production such as 
human and defensins and human cathelicidin LL-37 by the lung epithelial 
cells and alveolar macrophages (Méndez-Samperio et al., 2008; Rivas-
Santiago et al., 2005; Rivas-Santiago et al., 2008), and influx of neutrophils 
into the airways (Laube et al., 2006). This leads to an immediate extracellular 
microbicidal effect on the invading bacilli in the lungs. The greater 
susceptibility of the rv1258c mutant to AMPs may thus explain the reduced 
bacterial load compared to WT strain seen in the mouse lungs during the acute 
phase of infection. However, the viability of rv1258c at day 5 post-infection 
of resting macrophages and in mouse lungs during the chronic phase of TB 
infection was comparable to that observed with the WT strain. These 
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observations seem to suggest that the Rv1258c protein is not critical for the 
intracellular survival of Mtb, but rather contributes to Mtb survival in the 
extracellular milieu.  
The inability of both WT and rv1258c mutant to thrive within the lung 
epithelial cells during the first two days of infection proved that these cells do 
possess a highly potent microbicidal activity. Indeed, the production of human 
 defensin-2 in A549 cells has been associated with intracellular disrupted 
bacilli (Rivas-Santiago et al., 2005).  The surge in bacterial load in the later 
time of the infection might be either due to their immuno-incompetent nature 
to control Mtb infection, or that their microenvironment has become favorable 
for replication. For instance, the production or stability of AMPs might have 
been reduced during the later phase of infection, thus consequently affecting 
its killing efficacy on the bacilli. 
Taken together, we therefore hypothesize that the membrane-associated 
Rv1258c protein might be involved in the export or biosynthesis of cell wall 
components that are important for Mtb to establish an infection within its host. 
As reviewed in Section 4.1, there is indeed ample evidence of the 
mycobacterial efflux pumps as part of the coupled biosynthesis/export 
machinery of mycobacterial cell wall components, and their respective 
mutants displayed a loss in virulence during macrophage and mice infection. 
Work is underway to further examine the integrity and composition of the cell 
wall of the rv1258c mutant in comparison to the parental and complemented 
Ox-rv1258c strains, as detailed in Chapter 5. 


















Figure 4.12: Schematic representation of the cell envelope of Mtb. 
The components include the (A) plasma membrane, (B) peptidoglycans, (C) 
arabinogalactan, (D) mannose-capped lipoarabinomannan, (E) plasma 
membrane- and cell envelope-associated proteins, (F) mycolic acids and (G) 
glycolipid surface molecules associated with the mycolic acids (Reprinted 
from Cellular Microbiology, Vol 6/2, Karakousis et al, Mycobacterium 
tuberculosis cell envelope lipids and the host immune response, 105-116., 





















Figure 4.13:  Schematic presentation of proposed mechanism of actions of 
AMPs. Three major models depict how cationic amphipathic AMPs insert into 
lipid bilayers to form ion channels and transmembrane pores or lead to 
membrane disruption. Hydrophilic and lipophilic parts of the AMPs are 
indicated in light grey and black respectively. (Reprinted from Virulence, Vol 
1/5, Wiesner & Vilcinskas, Antimicrobial peptides: The ancient arm of the 
human immune system, 105-116., Copyright (2010), with permission from 
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5.1. Final conclusion  
The macrophage has been widely recognized as the primary host cell for Mtb. 
As an intracellular pathogen, survival of Mtb within the resting macrophage 
has been extensively studied and attributed to its ability to halt the process of 
phagosome maturation. A number of mycobacterial factors have been 
identified to play a role in the phagosome maturation arrest via interacting and 
interfering with a number of host proteins and pathways. However, upon 
activation of the infected macrophages, the mycobacteria-containing 
phagosome fuses with lysosomes, which exposes the bacilli to a very hostile 
microenvironment. In this thesis, we sought to further study and identify novel 
mechanisms that could potentially contribute to the intracellular survival of 
Mtb within the phagolysosomal compartment.  
The first mechanism that we investigated was the role of the mycobacterial 
urease activity. This hypothesis was based on the fact that a number of 
pathogenic bacteria are known to resist acidic conditions, and thereby 
contribute to the pathogen’s virulence through their urease activity. Our work 
however established that the urease activity of Mtb exerts a modest alkalizing 
effect within the acidic phagolysosome of activated macrophage, which does 
not confer any advantage to intracellular survival. Instead, we found that Mtb 
is able to utilize urea as an energy source for in vitro growth through its urease 
activity, once again highlighting the metabolic versatility of the pathogen. This 
finding also emphasizes the importance of comprehending the actual 
metabolic needs of Mtb during in vivo infection in order to derive better 
targeted drug and vaccine designs.  
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Microarray studies based on macrophage and mouse infection models of Mtb 
have extensively profiled its intracellular transcriptome. To elucidate 
phagolysosomal-induced mechanisms of Mtb survival and persistence, we 
developed a novel in vitro lysosomal exposure model, in which Mtb is 
exposed directly to the soluble fraction (SF) of lysosomes extracted from 
activated macrophages. Through next generation sequencing and analysis of 
RNA-Seq data, we profiled the transcriptome of Mtb during in vitro lysosomal 
exposure and observed significant transcriptional changes. Meta-analysis 
revealed that there is minimal overlapping of these differentially expressed 
genes with previous macrophage or mouse infection based microarray studies, 
which indicated that our in vitro lysosomal model is a partial recapitulation of 
the various niche environments encountered during infection of macrophage 
or a whole mouse. Most importantly, our model had identified new 
mycobacterial genes, and enriched for a cluster of phagolysosomal-inducible 
mycobacterial transporters, implying a potential role in intra-phagolysosomal 
survival of Mtb. Among the genes whose expression was significantly 
modulated upon exposure to SF, rv1258c-encoded Tap efflux pump appeared 
to be a promising and obvious candidate that may play an important role in the 
intra-phagolysosomal survival of Mtb. We established that the efflux activity 
of the Rv1258c protein is not responsible for resisting the in vitro lysosomal 
killing. Greater susceptibility to purified AMPs, and reduced infectivity and 
viability early during macrophage and mice infection of rv1258c mutant 
compared to its parental counterpart pointed to a possibility of a cell-wall 
associated role of the membrane associated Rv1258c protein. Further work is 
nevertheless necessary to establish its role in Mtb virulence.  
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In conclusion, understanding the fundamental mechanisms involved in 
pathogenesis remains critical to the successful design of effective therapies. 
Undeniably, the versatility exhibited by Mtb, through a growing repertoire of 
mechanisms, represents its key success to persist within its human host. The 
work of this thesis is part of the scientific quest to unravel novel mechanisms 
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5.2. Future directions 
We hypothesized that the membrane associated Rv1258c protein might be 
involved in the export/biosynthesis of some cell wall components of Mtb. It is 
therefore of priority to establish if there is difference in the cell wall 
composition of rv1258c mutant to the parental and complemented strains 
through the following approaches: 
  
Analysis of whole cell wall composition 
The loss in cell wall integrity could be described either as a change in cell wall 
composition or the loss of cell wall components. Thin layer chromatography 
(TLC) will be employed to analyze the composition of whole cell, extractable 
and cell wall bound lipids of the Mtb strains. Changes in the mycolic acid 
profile have been described to impact significantly on Mtb virulence (Liu et 
al., 1996). Electro-spray ionization-based multiple reaction monitoring (ESI-
MRM) mass spectrometry will also be performed to quantify and qualify the 
profiles of various species and sub-species of mycolic acids (Takayama et al., 
2005). 
 
Cell wall permeability assay 
To further support the observation that rv1258c displayed increased 
susceptibility to purified AMPs, we propose to perform cell wall permeability 
assays using agents which specifically target the cell membrane such as sodium 
dodecyl sulfate (SDS) and polymyxin B, and compare the susceptibility of the 
rv1258c to the parental and complemented strains. Also, CCCP can be added to 
determine if the efflux activity of Rv1258c protein is involved. Lower MICs of 
cell wall permeable antibiotics such as rifampicin have been shown to not always 
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correlate with increased cell wall permeability (Camacho et al., 2001; Jackson et 
al., 1999), hence not a good indicator of membrane permeability.  
 
Analysis of immune-correlation to cell wall composition 
The cell wall lipids and glycated proteins of Mtb are known to activate 
macrophages and confer strong immune responses by generating several 
protective mechanisms leading to generation of nitric oxide (NO) and a wide 
variety of cytokines and inflammatory mediators (Brennan, 2003; Brightbill et 
al., 1999; Herbst et al., 2011; Schlesinger, 1993). Arya and colleagues have 
also shown that the increased accumulation of lipids and glycosylated 
truncated haemoglobin (HbN) on the cell membrane and the cell surface led to 
elevated levels of inflammatory cytokines, IL-6 and TNF-α that are known to 
regulate expression of inducible nitric oxide synthase (iNOS) and NO 
production, in mouse peritoneal macrophages (Arya et al., 2013). Conversely, 
the loss of cell wall lipids and glycated proteins could be correlated to the 
reduced production of these cytokines. Through ELISA, the production of 
these cytokines by macrophages infected with rv1258c mutant can be 
measured, and compared to that of the parental and complemented strains. 
 
In addition, the RNA-Seq data have also led to the identification of other gene 
candidates whose expression is significantly modulated during exposure to SF. 
This provides the opportunity to study the role of a number of these genes in 
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Appendix 1: Composition of bacterial culture media 
1.1. E.coli culture media 
 
1.1.1. Luria-Bertani (LB) Broth 
Component Per litre 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
  
Autoclave at 121°C for 15 min  
 
1.1.2. Luria-Bertani (LB) Agar 
 
 
1.2. Mtb culture media 
 










Component Per litre 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
Agar 15 g 
  
Autoclave at 121°C for 15 min  
Component Per litre 
Bovine Albumin (Fraction V) 50g 
Dextrose  20g 
Sodium chloride 8.5g 
  




1.2.2. Middlebrook 7H9 broth 
Component Per litre 
Ammonium Sulfate  0.5 g 
L-Glutamic Acid 0.5 g 
Sodium Citrate 0.1 g 
Pyridoxine 1.0 mg 
Biotin 0.5 mg 
Disodium Phosphate 2.5 g 
Monopotassium Phosphate 1.0 g 
Ferric Ammonium Citrate 0.04 g 
Magnesium Sulfate 0.05 g 
Calcium Chloride 0.5 mg 
Zinc Sulfate 1.0 mg 
Copper Sulfate 1.0 mg 
ADS enrichment 100ml 
Tween-80 0.5g 
  
Filter sterilize with 0.22 m filter unit  
 







Component Per litre 
Ammonium Sulfate  0.5 g 
L-Glutamic Acid 0.5 g 
Sodium Citrate 0.1 g 
Pyridoxine 1.0 mg 
Biotin 0.5 mg 
Disodium Phosphate 2.5 g 
Monopotassium Phosphate 1.0 g 
Ferric Ammonium Citrate 0.04 g 
Magnesium Sulfate 0.05 g 
Calcium Chloride 0.5 mg 
Zinc Sulfate 1.0 mg 
Copper Sulfate 1.0 mg 




Autoclave at 121ºC for 10 minutes 5ml 




1.2.4. Dubos broth 
Component Per litre 
Pancreatic Digest of Casein 0.5 g 
L-Asparagine 2.0 g 
Disodium Phosphate 2.5 g 
Monopotassium Phosphate 1.0 g 
Ferric Ammonium Citrate 0.04 g 
Magnesium Sulfate 0.05 g 
Calcium Chloride 0.5 mg 
Zinc Sulfate 1.0 mg 
Copper Sulfate 1.0 mg 
Dubos medium albumin (Difco) 100ml 
Tween-80 0.5g 
  
Filter sterilize with 0.22 m filter unit  
 
 
1.2.5. In-house minimal medium 
Component Per litre 
Ammonium Sulfate 2.5 g 
Disodium Phosphate 1 g 
Pyridoxine 1 mg 
Biotin 0.5 mg 
Ferric ammonium citrate 15 mg 
Magnesium Sulfate 40 g 
Calcium Chloride 0.5 mg 
Zinc Sulfate 0.6 mg 
Copper Sulfate 0.6 mg 
Sodium chloride 0.8 g 
Tyloxapol 0.5 g 
Fatty-acid free bovine serum albumin  (BSA) 1g 
Glycerol 2g 
  












Appendix 2: Reagents for Southern Blot  
2.1 Depurinating solution 
 
2.2 Denaturing solution 
 
2.3 Neutralisation solution 
 














Concentrated HCl (37%)  
Component Per litre 
Sodium hydroxide  20g 
Sodium chloride 87.5g 
Component Per litre 
Ammonium acetate 20g 
Sodium hydroxide 87.5g 
Component Per litre 
3M Sodium chloride  




Appendix 3: Composition of cell culture media 
3.1 BMMO complete culture medium 
 
 






Component Per litre 
DMEM with high glucose (Gibco) 870ml 
100mM Sodium pyruvate (Gibco) 10ml 
Fetal bovin serum (Gibco) 100ml 
1M HEPES (Gibco) 10ml 
10000U/ml  Penicillin-Streptomycin 10ml 
  
Filter sterilize with 0.22 m filter unit  
Component Per litre 
RPMI 1640 medium (Gibco) 870ml 
Fetal bovin serum (Gibco) 100ml 
GlutaMAX (Gibco) 1ml 
10000U/ml  Penicillin-Streptomycin 10ml 
  





















Figure A4.1: pYUB854 plasmid. Two multiple cloning sites, MCS 1 and 2, 
flank the hygromycin resistance cassette, as indicated by the two clusters of 



















Figure A4.2: pGOAL plasmid. PAg85-lacZ Phsp60-sacB can be excised using 









































Figure A5.2: Base per quality quantile (QQ) plots of reads sequenced in 
(A) forward and (B) reverse direction for RNA-Seq data for one of the 
Mtb mRNA samples. RNA-Seq data for all samples depicted similar trends in 



















































Figure A5.3: Real-time PCR analysis of rv1257c expression in Mtb 













































































Appendix 6: RNA-Seq data analysis and meta-analysis 
Table A6.1: List of Mtb genes induced in in vitro lysosomal exposure model and compared to other models of TB infection. 
Functional 






Fold change (values from each study) 
Homolka, 2010 Schnappinger 2003 Rohde, 2012 
Talaat















Cell wall and 
cell processes 
(Transport) 




7.997 0.0000     1.7 1.5         




2.240 0.0401                 




2.322 0.0292                 
MT2040 Rv1986   Putative amino-acid transporter  2.680 0.0149     2.8 3.1         




3.392 0.0023                 



















4.616 0.0002     1.5 2.7         





7.825 0.0000                 
Hypothetical 
MT0115 Rv0106     2.420 0.0244                 
MT0834 Rv0813c     2.578 0.0155             1.38 2.22 
MT1160 Rv1128c     5.556 0.0000 4.03 5.79 3.6 3 1.83       
MT1508 Rv1461     2.916 0.0056 2.65 2.07 2.4 3.6 1.71       
MT2903 Rv2837c     2.504 0.0171         0.79       
MT2981 Rv2913c     2.302 0.0329     2.7 2.6         
MT0148       2.203 0.0450                 
MT0222       3.250 0.0027                 
MT0263       2.421 0.0220                 
MT0264       5.987 0.0000                 
MT0362       3.692 0.0010                 
MT0363       2.602 0.0155                 
MT0364       2.645 0.0168                 
MT0575       2.839 0.0289                 
MT0697       2.879 0.0073                 




MT1020       2.194 0.0423                 
MT1073       2.360 0.0263                 
MT1078       3.379 0.0027                 
MT1164       2.473 0.0186                 
MT1192       3.838 0.0118                 
MT1279       2.409 0.0388                 
MT1507       3.171 0.0044                 
MT1509       2.697 0.0103                 
MT1513       3.583 0.0016                 
MT1774       3.047 0.0083                 
MT1795       2.771 0.0179                 
MT1817       2.429 0.0399                 
MT1854.1       2.246 0.0454                 
MT1957.1       8.244 0.0000                 
MT1958       6.809 0.0000                 
MT1979       2.797 0.0103                 
MT2004       5.819 0.0000                 
MT2006       2.380 0.0282                 
MT2072       3.549 0.0015                 
MT2075       2.462 0.0347                 
MT2488.1       2.587 0.0275                 
MT2541       2.634 0.0128                 
MT2854       2.423 0.0250                 
MT2890       2.748 0.0108                 




MT3078       2.285 0.0424                 
MT3080.1       5.963 0.0001 1.3 2.02     1.413       
MT3140       4.278 0.0003                 
MT3277       2.689 0.0145                 
MT3561       2.200 0.0445                 
MT3569       2.690 0.0151                 











3.730 0.0011     2.6 2.7 1.50       
              
MT1296 Rv1257c   Probable oxidoreductase 2.624 0.0127                 
MT1338 Rv1299  prfA Peptide chain release factor 1 2.394 0.0231                 
MT1339 Rv1300 papM Protein hemK homolog 2.247 0.0351                 




2.415 0.0222 2.08 1.72 1.6 3.4 1.12       










2.161 0.0452                 






2.642 0.0120 1.49 1.68 1.9 2         
MT2797 Rv2725c hflX Probable GTPase 2.892 0.0061                 




2.626 0.0121                 




e, putative   




















2.362 0.0271     1.9 2.8         











MT0928 Rv0905 echA6 Probable enoyl-CoA hydratase  2.206 0.0407                 




3.915 0.0005     7.5 4.8 2.00       




3.925 0.0005     4.2 2.8 1.27       





2.400 0.0263                 
MT2515 Rv2439c proB Glutamate 5-kinase 2.278 0.0403         0.64       





2.805 0.0080                 
MT2967 Rv2899c fdhD Protein fdhD homolog 2.515 0.0196                 




2.336 0.0272                 




5.449 0.0000 1.77 1.7     1.37       




6.600 0.0000                 








PE/PPE MT0369 Rv0354c ppe7 PPE family protein PPE7 2.719 0.0105                 
Regulatory 
proteins 





3.644 0.0011 1.57 1.49             




3.648 0.0011     2.1 2.5         
MT2039 Rv1985c   transcription regulator 2.377 0.0281                 







3.220 0.0048                 






6.637 0.0000 4.24 4.56 3.1 1.7 2.17       
MT3941 Rv3833   araC family 2.632 0.0179     2 2.2     1.96 4.74 
MT0206     Transcription regulator 2.813 0.0116                 
MT0481     transcription regulator 2.466 0.0196                 
MT0605     arsR family 2.222 0.0380                 




MT0698       2.822 0.0077                 
MT0750       2.423 0.0244                 
MT1161       9.452 0.0000                 
MT1510       2.853 0.0070                 
MT1519       2.159 0.0460                 
MT2005       5.290 0.0001                 
MT2073       3.514 0.0017                 
MT2312       2.507 0.0205                 





MT0265 Rv0251c hsp Heat shock protein 7.184 0.0000 2.34 3.41 31.9 34.3 2.38   1.63 5.79 




4.032 0.0004 2.17 2.66 2.7 3 1.58       
MT0366 Rv0351 grpE Probable GrpE protein 3.536 0.0012 2.43 2.79 2.1 1.8         
MT0367 Rv0352 dnaJ 1 Chaperone protein  2.704 0.0099                 






MT0456 Rv0440 groEL2 
60 kDa 
chaperonin 2 3.352 0.0018 1.6 2.01     2.02       
MT1959 Rv1908c  katG Catalase-peroxidase 2.775 0.0081                 
MT2008 Rv1959c parE Possible toxin 2.573 0.0281                 




5.795 0.0000     1.8 1.3         
MT3526 Rv3417c groEL 60 kDa chaperonin 1  4.977 0.0001             1.47 2.66 
MT3527 Rv3418c groS 10 kDa chaperonin 3.657 0.0009           M     
 
a Gene annotations are obtained from TB Database (http://www.tbdb.org). b Fold change is calculated by taking the ratio of RPKM values 




Table A6.2: List of Mtb genes repressed in in vitro lysosomal exposure model and compared to other models of TB infection. 
 
Function 







Fold change (values from each study) 
Homolka, 2010 Schnappinger, 2003 Rohde, 2012 
Talaat, 




















E-03         






E-03         






E-04         






E-03         






E-02   0.4 0.2     






E-02 0.47 0.53       






E-02   0.4 0.2     















E-02   0.4 0.3     






E-02         






E-02   1.7 2.4     






E-06 5.53 3.7     23.35 16.15 






E-02 2.88 1.73 1.1 3.1   10.26 5.52 
Unknown 
MT1440.1    
-2.695 
1.427
E-02         
MT3177    
-3.363 
2.094
E-03         
MT3453    
-2.157 
4.448
E-02         
Regulatory 
proteins 






E-02   1.9 2.8     











MT1009 Rv0981 mprA Response regulator 
-2.434 
2.183
E-02         





E-02   1.5 2.3     
PE/PPE 





E-02         
MT0298 Rv0285 pe5 PE family protein PE5 
-2.960 
8.788









E-02         





E-02         





E-02         
MT1233 Rv1195 pe13 PE family protein PE13 
-8.520 
4.571
E-07       3.76 0.95 
MT1234 Rv1196 ppe18 PPE family protein PPE18 
-6.745 
2.628
E-06      M   





E-02         














E-03       1.76 2.69 
MT1837 Rv1788 pe18 PE family protein PE18 
-2.658 
3.989
E-02   0.6 0.5     
MT2166 Rv2107 pe22 PE family protein PE22 
-5.674 
7.316









E-02         





E-02         





E-02         
MT3581 Rv3477 pe31 PE family protein PE31 
-3.740 
1.351
E-03   0.4 0.2  M   
MT3582 Rv3478 ppe60 PE family protein PPE60 
-4.052 
5.153
E-04   0.3 0.3  M   
Metabolism 
(lipids) 








E-02         

















E-03         






E-02         








E-02         







E-02         







E-02         





E-02   2.2 3.2   7.74 0.81 






E-02         






E-03   1.8 2 2.47    







E-03         
MT3169 Rv3084 lipR Probable acetyl-
-5.292 3.093














E-04     1.12    






E-05         







E-03         





E-07 3.43 2.28 2.2 13.8  M 22.4 33.35 







E-02   0.9 2.2     






E-02         






E-03       2.77 3.48 
















E-06         














E-02         








E-03         




protein A 3 
-6.332 
7.846
E-06     0.77    






E-02         






E-02   1.9 2.9  M   






E-03   1.7 2.2     
MT0091 Rv0084 hycD formate hydrogenlyase 
-2.316 
3.813
E-02   1.7 2     
MT0092 Rv0085 hyfE hydrogenase-4 component E 
-3.049 
1.081
E-02         
MT0093 Rv0086 hycQ Possible hydrogenase 
-2.882 
8.375












E-03         






E-04         








E-02         







E-02         




protein C 2 
-4.169 
5.597
E-04         








E-04   1.4 2.8 1.48  2.73 1.81 
MT1106 Rv1076 lipU Possible lipase 
-3.378 
2.024
E-03         







E-03     0.96    
MT1224 Rv1187 pruA delta-1-pyrroline-5-
-2.587 1.546















E-03   1.9 2.4 3.30    
MT1449 Rv1405c   
-2.774 
8.243
E-03 2.61 1.8 5.2 7.1 0.70    
MT1545 Rv1497 lipL Probable esterase 
-2.864 
6.675
E-03         





E-02         








E-02         
MT1897 Rv1849 ureB urease beta subunit 
-2.697 
2.465
E-02         






E-02         
MT2063 Rv2007c fdxA ferredoxin 
-3.364 
5.643
E-03 3.38 2.63 1.8 11.2  M 38.12 41.63 

















E-02         






E-02         






E-04         







E-05         







E-03         









E-02         





E-03 2.81 2.38       






E-03         
























E-03         





E-02         





E-03         





E-02         

















E-03 2.46 1.78 1.5 5     
MT1680 Rv1642 rpmI 50S ribosomal protein L35 
-2.610 
1.935
E-02         
MT1823 Rv1773c  MT1823 
-2.268 
3.446
E-02         


















E-03         







E-02         





E-02         






E-02   0.3 0.3 1.22 M   







E-02         






E-04         








E-03   0.6 0.3     





E-02         












MT1924.1 NA   
-3.406 
6.300
E-03     0.50    
MT2167 NA   
-3.513 
1.706
E-03         
MT0908 Rv0885   
-3.739 
7.468
E-04   0.9 1.8   4.21 3.29 
MT1315 Rv1278   
-2.211 
4.004
E-02         
MT1780 Rv1738   
-6.154 
7.573
E-05 4.14 2.82 1.7 16.7  M   
MT1861 Rv1813c   
-2.735 
1.209
E-02   1.1 1.7   35.6 38.19 
MT2218 Rv2159c   
-2.744 
9.285
E-03     1.43    
MT2997 Rv2927c   
-2.273 
3.301
E-02 0.62 0.87 0.5 0.3     
MT3502 Rv3395c   
-2.575 
2.249




MT3820 Rv3717   
-2.321 
3.109
E-02 0.59 0.73       
MT0053    
-2.425 
2.203
E-02         
MT0086    
-6.914 
2.534
E-06         
MT0087    
-7.018 
4.355
E-06         
MT0176    
-2.348 
2.840
E-02         
MT0177    
-2.787 
1.002
E-02         
MT0326    
-2.311 
3.202
E-02         
MT0350    
-3.936 
1.679
E-03         
MT0356    
-8.563 
1.615




MT0357    
-2.334 
2.748
E-02         
MT0763    
-2.484 
4.660
E-02         
MT0844    
-2.202 
3.997
E-02         
MT1003.1    
-2.447 
2.021
E-02         
MT1025    
-2.751 
8.791
E-03     1.14    
MT1025.2    
-3.669 
9.806
E-04     0.96    
MT1026    
-3.035 
5.112
E-03         
MT1076    
-2.444 
2.666
E-02         
MT1105    
-2.187 
4.706
E-02         
MT1194    
-4.612 
1.974




MT1422    
-2.808 
8.225
E-03         
MT1479    
-3.472 
1.484
E-03         
MT1677    
-2.394 
2.493
E-02         
MT1729    
-3.329 
4.634
E-03         
MT1736    
-2.239 
3.575
E-02         
MT2089    
-10.249 
4.168
E-08         
MT2218.1    
-2.766 
1.225
E-02         
MT2222    
-2.200 
4.001
E-02         
MT2400    
-2.283 
4.769
E-02         
MT2420    
-2.597 
1.553
E-02 0.49 0.55   1.06    
MT2421    
-2.413 
2.463




MT2458    
-2.818 
8.421
E-03         
MT2459    
-3.575 
1.244
E-03         
MT2466    
-2.474 
2.030
E-02 3.7 3.54   6.18    
MT2794    
-2.679 
1.077
E-02         
MT3093    
-2.358 
3.713
E-02         
MT3173    
-4.093 
3.615
E-04         
MT3178    
-2.759 
9.374
E-03         
MT3217    
-2.565 
3.464
E-02         
MT3305    
-2.333 
3.215
E-02         
MT3356    
-2.301 
3.528
E-02         
MT3423    
-2.513 
2.750




MT3462    
-2.596 
3.167
E-02         
MT3718    
-2.372 
2.457
E-02         
MT3763    
-3.066 
5.251
E-03         
MT3849    
-4.870 
6.823
E-05         
MT3930    
-2.791 
8.150
E-03         
MT3970    
-5.122 
5.252
E-05         













E-04   0.5 0.3     






E-03   0.4 0.3     






E-04         
MT0300 Rv0287 esxG ESAT-6 like protein 
-2.535 
1.981




MT1235 Rv1197 esxK ESAT-6 like protein 
-4.761 
1.132
E-04      M   
MT1236 Rv1198 esxL ESAT-6-like protein 
-3.530 
1.501
E-03         





E-02         







E-03         
















E-04         





E-03         




















E-02         










E-02     1.62    






E-03       3.06 0.71 







E-02         








E-02 1.43 1.93       





E-02         







E-02         

















E-02         
MT3870 Rv3763 lpqH Lipoprotein -2.561 
1.791
E-02   0.2 0.2     







E-02         






E-03         






E-02         
 
a Gene annotations are obtained from TB Database (http://www.tbdb.org). b Fold change is calculated by taking the negative of ratio of RPKM 
values expressed during SF buffer to that of SF exposure. M, modulated. 
 
 
 
 
 
 
 
 
